Vol. 2, 2043, December 1996 Clinical Cancer Research 2043

A �CR l�u1letin Board

Institution of Page Charges

Effective January 1, 1997. a page chargeof $35 per printed page will be leveled onall manuscripts published in C!inica! Can-

cer Research. It is understood at the time

of submission that the author(s) agree topay this charge in the event of publication.

Under exceptional circumstances, whenno other source of grant or other supportexists. the author(s) may apply to Dr.Margaret Foti, Director of Publications,AACR Publications Department (see pageii for address) at the time of submissionfor a waiver of the page charges. All suchapplications must be countersigned by an

appropriate institutional official statingthat no funds are available for the pay-ment of page charges.

Annual MeetingThe AACR’s Annual Meeting is one ofthe largest and most important annualgatherings of scientists engaged in cancer

research worldwide. The next AnnualMeeting will take place in San Diego. CA,April 12-16, 1997. The Chairperson ofthe Annual Meeting is Frederick P. Li ofthe Dana-Farber Cancer Institute. ClaraDerber Bloomfield of the Roswell ParkMemorial Institute and Stephen H. Friendof the Fred Hutehinson Cancer ResearchCenter will serve as Co-Chairpersons. TheProgram Committee has invited outstand-ing scientists in the field to organizeplenary sessions. symposia. controversysessions. and meet-the-expert sunrise ses-sions. They are also now reviewing the

proffered papers submitted by membersof the cancer research community. Thedeadline for abstract submissions was No-vember 12. 1996. Up-to-date program in-

formation can be obtained via the Internetat the AACR’s website (http://www.aacr.org/meetings.html).

Gertrude Elion Cancer ResearchAwardApplications for the AACR’s 1997 Ger-trude Elion Cancer Research Award. sup-ported by an educational grant from GlaxoWelleome Oncology. are due Fchruars’

14, 1997. The one-year. $30,000 grant to anontenured Assistant Professor supportsmeritorious basic, clinical, or translational

research in cancer causation, prevention,or treatment. Tenured faculty in academia,government employees. and employees ofprivate industry are not eligible for thisaward. Information and application formswere mailed to AACR members and tothose who requested applications. Non-members should request information andapplications from the AACR office.

AACR Research FellowshipsThis year the AACR will offer at leastsix one-year, $30,000 research fellow-

AACRThe American Association for CancerResearch (AACR) was founded in 1907to bring together active investigators ofthe cancer problem for the presentationand discussion of new findings and tofoster advances in cancer research. To-day the Association has more than1 1 ,000 members working in all of thesubdisciplines of cancer research in the

United States, Canada. and more than50 other countries. Information onAACR programs and activities can beobtained from

American Association forCancer Research

Public Ledger Building150 South Independence Mall West

Suite 816Philadelphia, PA 19106-3483

Phone: (215) 440-9300Fax: (215) 440-9313

The AACR welcomes applications formembership from the readership. Scien-tists engaged in all areas of cancer re-search are eligible for membership.There are three categories of member-ship: active membership, open to cancerresearchers working in the Americas:corresponding membership. to thoseworking outside the Americas: and as-

sociate membership. to graduate andmedical students, postdoctoral fellows,and physicians-in-training. Further in-formation on the qualifications for eachcategory as well as the benefits of mem-bership can be found on the application

forms at the back of this issue.

ships for clinical or postdoctoral fellows

working in the U.S. or Canada. Infor-mation and a universal application formwill be mailed to all AACR Members inthese countries and to others upon re-quest for any of the following: the Re-search Fellowship in Clinical Research,sponsored by Bristol-Myers Squibb: theResearch Fellowship in ClinicaliTrans-lational Research, sponsored by Amgen:the Research Fellowship in Prevention,sponsored by the Cancer ResearchFoundation of America; and three Re-search Fellowships in Basic Research,sponsored by The Sidney KimmelFoundation for Cancer Research,Hoechst Marion Roussel, and theAACR. Additional fellowships andsponsors may be announced. To be eli-gible for these fellowships. candidatesmust have completed the M.D., Ph.D.,or other doctoral degree. Candidatesmust currently be a postdoctoral or elm-icab research fellow and must have beena fellow for at least two years but not

more than five years prior to the year ofthe award. The deadline for applicationsfor the research fellowships is Friday,February 14, 1997.

AACR Special Conferences inCancer Research

A number of meetings are now beingorganized in the AACR’s series ofsmaller scientific meetings. Followingare the topics. dates, locations. and pro-gram committees for some of thesemeetings. When full details of eachmeeting are available, AACR memberswill be the first to receive complete bro-ehures and application forms for partic-ipation in these important conferences.Nonmembens may receive this informa-

tion by sending their names and addressesto Meetings Mailing List, American As-sociation for Cancer Research, Public

Ledger Building, 150 South Independence

Mall West, Suite 8 16. Philadelphia. PA19106-3483. Telephone: (215) 440-9300.FAX: (215) 440-9313. E-Mail: aacr@aaer.org. Up-to-date program informationis available via the Internet from the

AACR’s website (http:llwww.aaer.org/eonfrnc.html).

January 10-14, 1997Basic and Clinical Aspects ofLymphoma

Joint ?vleeting wit/i tile America,z Society

of C!inica! Onco!ogv

Chairpersons:

JOSEPH R. BERTINO. New York,NYJAMES 0. ARMITAGE. Omaha, NEStouffer Renaissance EsmeraldaResort, Indian Wells (Palm Springs),CA

March 7-12, 1997Basic and Clinical Aspects of Breast

Cancer

Chairpersons:

J. CARL BARRETF. Research TrianglePark, NC

KAREN S. H. ANTMAN, New York,NYMARY-CLAIRE KING, Seattle, WAKeystone Resort, Keystone. CO

June 7-11, 1997

Cancer of the Central Nervous System

Conference with Neurosurgery Joint

Section on Tumors

Chairpersons.’

PETER MeL. BLACK, Boston, MAWEBSTER K. CAVENEE, La Jolla,CALoews Coronado Bay Resort, SanDiego, CA

Vol. 2. 2045-2047, December /996 Clinical Cancer Research 2045

‘*October I. 1995 - September 30, 1996.

Acknowledgment to Reviewers

The Editor-in-Chief, the Associate Editors, and the Editorial Advisory Board acknowledge with appreciation the assistance of the following

individuals who have generously contributed their time and effort during the past year� to review manuscripts for Clinical (�ancer Research. The

quality of the journal can be attributed in large measure to the quality of their effirt, for which we are sincerely grateful.

A

Stuart A. Aaronson

Reed Adams

G. Adema

Carol Aghajanian

David Agus

Mark AlbertiniFrancis Ali-Osman

Suresh Ambudkar

Kenneth Anderson

Marshall W. Anderson

Paul AndersonKian Ang

Jack I. ArbiserSusan G. Arbuck

Ralph B. Arlinghaus

Carlos Arteaga

Vasilios Assikis

Michael B. Atkins

B

Debabrata Banerjee

Menashe Bar-EliRichard BarakatLini Bartlett-Pandite

Jose Baselga

Susan Bates

Atul BediDorthea BekkerWilliam Bellamy

William Bennett

Christopher Benz

Andrew BerchuckMichael Berens

Nathan Berger

Ira BergmanNancy Berliner

Ralph BernackiDonald BerryJoseph Bertino

Kapil N. Bhalla

Jaclyn Biegel

Darrel D. Bigner

Archie Bleyer

Carl BlomqvistArthur W. Boddie, Jr.

Michael Bookman

Anne-Lise Borresen

Piet BorstJeffrey BoydGleen BranoffMichael G. Brattain

Eric Bremer

Dean E. Brenner

Vli Brinkeman

Jim BrooksBarry Brown

Carol BrownPowel Brown

Hal E. BroxmeyerH. Broxterman

Corazon BucanaDonald Buchsbaum

Paul BunnAntonio Buzaid

C

Paul Cairns

Mitchell Cairo

Michael Caligiuri

Lisa Cannon-Aibright

Giovanni Capranico

David Carbone

Michael CarducciAshele Carlo

Jorge Carrasquilbow. E. Carson

Ronald Cartenhaus

Terrence CascinoDoug CaseDiana Casper

Raju Chaganti

Richard Champlin

Paul ChapmanMartin Cheever

Luci Chen

Yung-Chi Cheng

Bruce D. ChesonJia Lin Chou

Randolph Christen

Kathy Christman

Gary M. ClarkPinchas Cohen

Daniel Coit

Thomas H. Corbett

C. Cordon-CardoJoseph M. Corey

Marion Couch

Patrick J. Creaven

S. P. CreekmoreR. CrystalKevin Cullen

David Cunningham

Brendan Curti

John P. Curtin

D

William Dahut

William S. Dalton

Robert DamatoPeter Danenberg

Mary K. Danks

Ian DavidAndre Davidoff

Nancy Davidson

Lisa M. Deangelis

A. De La ChapelleGeorge D. DemetriSamuel Dermeale

Beth DeutchRussell Devore

G. E. Dc VriesTheodore Deweese

Daniel Dexter

Kapil DhingraAlan M. Diamond

Chaitanya R. Divgi

Ethan DmitrovskyLawrence A. Donehower

M. Dowsett

Glenn DranotI

Anatoly Dritschilo

E

Janet EarylGail Eckhardt

Stephen Egde

Janine Einspahr

Elizabeth A. EisenhauerWafik S. El-Deiry

Richard Elledge

Matthew Ellis

Mike Emmertbuck

Adel K. El-Naggar

Elihu Estey

Sharon Evans

F

Thomas J. Fahey

Dominic Fan

David C. Farrogia

Alexander FeferCarolyn Felix

Robert A. Fenton

Rena FernmanNapoleon Ferrara

Soldano FerroneRobert Figlin

James Finke

Jonathan L. Finlay

Richard Fisher

Kathy FlandersGini F. Fleming

Jonathan A. Fletcher

Carlos Flombaum

Antonio T. Fojo

Kwun FongKeeneth A. Foon

David A. Foster

Paula M. FracassoArnold Freedman

Eileen Friedman

Herbert FritscheJohn Fruehauf

Yasuhiro Fujiwara

Minoru Fukuda

Bernard Futscher

G

Janice Gabrilove

John GalivanGary GallickSteven GallingerVarsha Gandhi

Giampietro Gasparini

Adi F. Gazdar

Akihiko Gemma

Robert Gemmill

Eugene W. GernerStanton L. GersonAlan Gerwitz

Maria-Ana Ghetie

Cecilia M. Giaehilli

Tern GilewskiStephen Gillies

Claude GimmiBeppin Giovanella

Ruth A. GjersetEli Glatstein

Bonnie Glisson

David Goldenberg

Jared Gollob

Michael Gordon

Michael Gottemsan

Michael Gould

Kenneth Grabstein

Stephen GrazianoAnthony GrecoMark GreenJean Grem

Liam Grogan

Michael Grossbard

H. Bartgon Grossman

Stephen GruberF. Peter Guengerich

Jose G. GuillemElora GuptaHiral L. GurtooGordon Gutterman

2046 Acknowledgment to Reviewers

H

Peter HafkmeyerWilliam N. Hait

Ruth Halaban

Dennis HallahanHoward HalpernThomas C. Hamilton

James W. Hardin

Steadman Harrison

John HausdorffHarald Zur Hausen

M. J. HawkinsRuth Heimann

Martin HemlerMeenhard Herlyn

James E. Herndon, II

Warren Heston

Steven HillSamuel Ho

Robert Hoffman

Jeff HoltChung I. Hong

Gabriel N. HortobagyiDavid P. Houchens

Alan HoughtonWilliam J. M. Hrushesky

Peng Huang

Robert Huben

Clifford HudisMien Chi HungPaul Hutson

Patrick Hwu

Nancy Hynes

I

John T. IsaacsMark Israel

J

Ann L. Jackman

Gerrit JansenRobert Jenkins

Suresh C. JhanwarBruce Johnson

David JohnsonMichael Johnson

V. Craig Jordan

Joseph JurcicMalik Juweid

K

Jacob KaganBurton A. Kamen

Crystal KanerHagop KantarjianJames P. KarrSeymour KaurmanFrederic J. KayeAbbruzzesel KhuriFadbo Khuri

Gretchen KimmiekHedy Lee KindlerKenneth Kinzler

E. S. KleinermanHynda K. Kleinman

David KnowlesMaggie KnowlesSusan J. Knox

Wayne Koch

Elise C. Kohn

Kristin KomschliesSteven Kornblau

Robert KreitmanMark G. K.ris

Davud Krizman

Susan Krown

Athanassios P. Kryitsis

John G. Kuhn

Rakesh Kumar

Jonathan KunieJohn F. Kutteseh, Jr.

L

Steven Larson

Julia LawrenceJ. Jack Lee

Jin Soo Lee

Mong Hong Lee

Sam W. Lee

Catherine LeitchHeinz-Josef Lenz

Ellis LevineFrank LiebermanEugene W. LingerIlona LinnoilaMartin Lipkin

Scott LippmanAlan List

Virginia A. Livolsi

Charles Loprinzi

Gemt LosReuben LotanScott Lowe

M

Greg MacewenBruce Mackay

Timothy MaddenDavid Mahvi

Louis MalspeisDaniel C. Maneval

Sridhar ManiA. Mantovani

Li MaoSanford MarkowitzMary Beth MartinM. Jules MattesHelena MauceriJohn D. McConnelTimothy J. McDonnell

Cornelius McGinnRobert J. Melder

Stephen J. MeltzerNeal J. Meropol

Edward M. Messing

Joseph Michaeli

James Mier

Tom MikkelsenGerard MilanoLangdon MillerWilson Miller

Gordon MillsSin MineishiJames B. Mitchell

Margalit MokyrT. Monig

Terry W. Moody

M. J. Moore

Malcolm A. S. MooreRichard MoranJoanne Mortimer

Robert Motzer

Elaine A. Muchmore

Franco Muggia

Carolyn MullerSharon Murphy

James Lee MurrayRuth MusehellJeffrey Myers

N

David Nanus

Alfred Neugut

Stephen Nimer

Perry NisenJohn L. NitissJames C. Norton

Gabriel Nunez

0

Augusto C. Ochoa

P. M. O’ConnorPeter J. O’Dwyer

Paul Okunieff

Susan Ostrand-Rosenberg

P

Paola A. Paciucci

R. PackerDavid L. Page

Lance C. PagliaroRamon Parsons

Jens Pedersen-Bjergaard

Anthone E. Pegg

Roman Perez-SoberJames J. PerryGodefridus J. Peters

Elizabeth M. PettyDavid PfisterJames Phan

Steven Piantadosi

Gary PiazzaKenneth J. Pienta

Stefano Pileri

Silvana Pilotti

Renate Pitz

David Piwnica-Worms

William K. Plunkett

Ian PollackMichael N. Pollack

Bruce PolskyYves Pommier

Carl Porter

Carol Portlock

William Powell

E. A. Poynor

Michael Prados

Harvey Priesler

R

Robert RadinskyA. RameswamyTimothy Rebbeck

Eddie Reed

Ralph A. Reisfeld

Elizabeth Repasky

Leonard ReynoDaniel Rifldn

Jinee Rizzo

Anita Roberts

Michael Robertson

James RoccoWilliam Rose

Neal Rosen

Maury Rosenstein

Miriam Rosin

Marsha Rosner

Eric Rowinsky

Eric H. Rubin

Stephen Rubin

Jeffrey RubnitzValerie W. Rusch

Youcef Rustum

S

Michael Sadelain

Nagahiro Saijo

David Salomon

Leonard B. Saltz

Michael K. Samoszuk

Leona D. Samson

D. S. R. Sarma

Stimson Schantz

David Scheinberg

Russell J. SchilderChristine Schold

S. Clifford Schold, Jr.

Jan H. Schornagel

Gary Schwartz

Sidney A. Scudder

Andrew SeidmanYoshitaka Sekido

D. SewellJatin P. Shah

Kevin Shannon

Walter J. Urba

U

V

Clinical Cancer Research 2047

Fred Shapiro

William Shapiro

Robert Sharkey

Thomas C. SheaDarryl Shibata

Moshe Shike

Dong M. Shin

Tzipora Shoshani

Clay B. Siegall

Branimir I. SikicLewis M. Slater

Kendall Smith

Martin Smith

Mitchell R. Smith

Thomas J. Smith

Harriet 0. Smitt

Mark Sobel

A. Sobrero

Mel SorensenLee Paijeff Sosman

Thierry Soussi

Lisa Speicher

Richard Spencer

Margaret Spitz

Michael B. Sporn

Georg F. SpringerWilliam Stetler-Stevenson

R. G. Stoller

Walter Storkus

Yan Su

Saraswati Sukamar

T

Raymond Taetle

Michael A. Tainsky

Chris H. Takimoto

Hiroshi Takita

Moshe Talpaz

Rajeshwar Rao TekmelNitin Telang

Franz Thiebaut

John Thompson

Joyce Thompson

Timothy Thompson

Snori Thorgeirsson

Philip E. Thorpe

Linda Titus-Ernstoff

Debra A. Tonetti

Giampaobo Tortora

Anthony Treston

Dean TroyerDonald Trump

Robert Tucker

Eva Turley

Juan Carbos Vera

Jacob Verweij

Ellen S. Vitetta

Cathy D. Vocke

E. E. Voest

Nicholas Vogelzang

Everett Vokes

Israel Voldavsky

w

Alan Wakeling

C. C. WangRaymond P. Warrell

William R. Waud

George Weber

Jeffrey WeberMichael Weinder

Louis Weiner

Howard J. Weinstein

I. Bernard Weinstein

Bernard Weissman

Steven D. Weitman

Anton Wellstein

Sidney Welt

Harold Werbin

Max Wicha

George Wilding

S. WilliamsMark C. Willingham

C. Roland Wolf

Renella WollEugene A. Wolterine

Y

Joachim Yahalom

Alan M. Yahanda

David YandellSamuel Yeh

Charles Young

Garret Yount

W. K. Alfred Yung

z

Daniel Zelterman

Wei Zhang

Karen Zier

Vol. 2. 2049-2054, December 1996 Clinical Cancer Research 2049

AUTHOR INDEX

Volume 2

A

Abad, A., 1083

Abbruzzese, J. L., 1489, 2015

Abraham. A.. 707

Ahlert, T., 21

Ahn, H-J., 1255

Aizawa, S., 1583

Akamatsu, K-i., 253

Akazawa, K., 763

Akiyoshi. T., 1619

Aksentijevich, I., 973

Alberti, D., 1299

Albertini, M. R., 319

Alberts, D. S., 947

Albino, A. P., 1077Alcaraz, A., 137

Aldaz, C. M., 1993

Allay, J. A., 1353

Allegra, C. J., 477

AIbred, D. C., 585, 1 199

Almadori, G., 175, 1895

Altenschmidt, U., 1001Alvarez, R. D., 1089

Alvord, W. G., 501

Anderson, D., 659

Anderson, J. M., 97

Anderson, L. W., 1481

Anderson, P. M., 721

Andersson, B., 1825

Andersson, M., 223

Ando, N., 909, 1155

Andreeff, M., 799

Andrews, P. A.. 991, 1859

Angeletti, C. A., 1067

Anker, L., 843

Antoine, E. C., 1405

Apostobi. P., 1829Apuzzo, M. L. J., 619

Araki, K., 1781

Araya, J. C., 1851

Arch, R., 447Arias, I. A., 695Ariza, A., 1083

Arteaga, C. L.. 207

Arzoomanian, R. Z.. 1299

ABmann, V., 1607

Assikis, V. J., 223

Atkins, M. B., 1341

Au, J. L-S., 1275

Aulitzky. W. E., I I 15

Avet-Loiseau, H., 1673

Avramis, V. I., 1533

Ayelbo, J., 873

Ayyagari, S. R.. 379

B

Baba, K., 1619

Badalament. R. A.. 1275

Bader, M., 287Badger, B., 1901

Bagshawe. K. D., 897

Bajorin, D. F., 295

Baker, J., 659

Baker, S. D., 1921

Balch, C. M., 419

Baldi, A., 1239

Baldi, F., I 239

Baluna, R., 1705

Bammer, T., 1031

Bank, A., 873

Banks, M., 1263

Banks, P., 1713

Barbareschi, M., 1591

Bar-Eli, M., 1969

Barbogie, B., 947

Barnes, M. N., 1089

Basolo, F., 1777

Bast, R. C., Jr., 81

Basu,J., 181

Bataille. R.. 1673

Batsakis, J. G., 903Battaglia, C., I 19

Bauman, L., 1685

Bauman, P. A., 97

Baylin, S. B., 805

Beck, N., 21

Becker, M., 457, 1289

Begemann, M., 1017, 1638

Begent, R. H. J., 897

Beger, H. G., 1469

Beijnen, J. H., 43, 1717

Bell, M. C.. 161

Bellacosa, A., 175, 1895

Belotti, D., 1725, 1843

Bench, K., 1717

Benedetti, F. M., 471

Benedict, W. F., 1 169

Benhammouda, A., 1405

Benhar, I., 1523

Benini, E., 2007

Bennett, W. P., 1767

Benson, P. D., 1543

Bentel, J. M., 277

Berchuck. A., 1571

Berd, D., 1383

Berger. M. S.. 735

Berger, N. A., 1649Bergman, A. M., 521

Bergstralh, E. J., 137

Berlingieri, M. T., 1 19

Bernhard, H., 1427Bertazzoli, C., 593Bertino, J. R.. 1819

Berzin. T. M.. 1445Berzofsky, J. A., 877

Bevilacqua, 0., 1067, 1777

Bevilacqua. P., 1 191

Bhardwaj. B.. 773

Bianchi, S., 261, 1577

Bianco, A. R., 207, 601

Bianco, C., 601

Bianco, R., 207

Bi#{232}che,I.. 1 163

Bigini, D., 1067

Bigler, S. A., 1039

Bigner, D. D., 963

Bigner, S. H., 963

Bird, R., 75

Bischoff, E. D., 511

Bischoff, E. K., 1859

Bitran, J. D., 1509

Bladou, F., 1039

Blagosklonny. M. V., 1221

Blamey, R. W., 923

Blank, A.. 735

Blaser, K., 593

Blumenson, L. E., 669

Bobola, M. S., 735

Boddi, V., 261, 1801

Bogenrieder. T., 1077

Boguniewicz. A., 1251

Bone, E. A., 1207Bonetti, A., 1829

Bonoldi,E., 1191

Bonzanini, M., 1591

Boon, P., 1009Boracehi, P., 1 191, 2007

Borchert, A., 319

Borden, E., 29Borel, C., 1405

Borell, T. J., 137, 883

Borowitz, M. J., 331Borsotti, P., 1843

Bourgeon. A.. 507

Bouyge, I.. 1673

Bower, M., 897Bowling, M. K., 1921

Brachman, D., 755

Bracy, D.. 947

Brandt, R. M. P., 1825Brennan, J. M., 549

Brenner, A. J., 1993Brinkmann, U., 1523

Brodeur, G. M., 1097

Brossart, P., 767

Brown, J. A., 137Brown, M. T., 963

Brown, R. W., 585Brown, T. J., 359

Brown, T. R., 339

Bruce, J. N., 1017, 1638

Brunette, E., 59

Bnjnner, N., 155

Bruntsch, U.. 1717Bucana, C. D., 1679, 1969

Buchanan, G., 277

Bucheik, R., 21

Budd, G. T., 347

Budning, A., 1499

Buhler, K. R., 1039Bukowski, R. M., 347

Bunch, R. T., 791Burns, D., 319

Burns, D. J., 201

Burns, P. A., 1795Bussolati, G.. 1757

Buttitta, F.. 1591

Butzer, U., 1469

C

Cadoni, G., 175, 1895

Caffo, 0., 1591

Cagle, P. T., 1169Caldarelli, D. D., 1453

Caliguri, M. A.. 669

Calvez, V., 47

Calzolari, A., 261, 1577

Camitta, B.. 331Campbell. P. A., 379Cantilena, L. R., Jr., 477Cao, S., 369, 707, 1961Capizzi, R. L., 1 107

Caputi, M., 1239

Caraglia. M.. 207

Carbone, D. P.. 877Cardarelli. C. 0.. 973Cardueei, M. A.. 379

Caron, D.. 1713Caron, G., 1767

Carter, C. A., I 143

Casazza. A. M.. 1725Case, L. D., I 107Casero, R. A., Jr., 441

Castelli, C.. 641

Castellsague, X., 1887

Castronovo, V., 1777Cavalli, F.. I 123, 1717

Cavallo, S., 175, 1895

Cawley. H. L., 1767

Cerutti, J., I 19

Cetto, 0. L., 1829Chambers, C. A., 1417

Chambers, J. T., 1693, 1699Chambers, S. K., 1693, 1699

Chamness. G. C., 1199Chan, H. S. L., 1499

Chan, K. K., 1461Chan-Tack, K. M.. 379

Chapman, P. B., 295, 679Chartier, S.. 493Chazal, M., 507

Chelstrom, L. M., 1533Chen, L. B., 1335Chen, T-L., 1481, 1921Chen, Y., 889

Cheo, D. L., 331

Cheshire, P. J., 107

Cheung. N-K. V., 1361

Chiarelli, I., 1577Chine, S., 1067Chinn, P., 457

Chitambar, C. R.. 1009

Chiu, J. J., 215Choi, J-J., 2029Choi. Y-j. A.. 1017, 1638Christiansen, K. M.. 1017, 1638

Chu, E., 477Ciardiello, F., 207, 601

Cidlowski, J. A.. 889

Ciernik, I. F., 877

Ciocca. D. R.. 1199

Cirisano, F. D.. 1571

Clark, G. M.. 585. 1 199Clary, B., 59

Clayman, G. L., 1659

Cleary. K. R.. 1679. 1999, 2015

Clemm, C.. 1565Clendeninn, N. J., 1685

Cliby, W., 1907

Cody, B. V., 295

F

G

2050 Author Index

Cohen, P., 837Cohn, S. L., 1097Colb#{232}re-Garapin, F., 47

Colby, T. V., I 767Coleman, C. N., 269

Coleman, M., 1751Coleman, R. E., 963

Collins, H., 493Collins, J. M., 953, 1481

Cobombatti, M., 1829Colvin, 0. M., 1481Connolly, J. M., 1751Conrad, N. K.. 1103Consoli, U., 1731Coon, J. S., IV, 1453

Coons, S. W., 187Cooper, M. R., 483Corneo, G. M., 593Comish, A. L., 923Cossette, N., 773Couldwell, W. 1., 619, 843Courjal, F., 1601Courtois, S., 1439Cowan, K. H., 215Creaven, P. J., 669

Cress, A. E., 97

Cristiano, R. J., 1665Crowley-Nowick, P. A., 161Cuartero-Plaza, A., 13

Cullen, K. J., 1859Curiel, D. T., 1089

Curley, S. A., 1397Curtis, D., 1039

D

Daidone, M. G., 2007Dakhil, S. R., 1285Dalla Palma, P., 1591

Dalton, W. S., 7, 97Damiano, V., 207, 601

Danforth, D. N., Jr., 827

Dante,S., 1191Das Gupta, T. K., 1391Daskal, I., 561Dave, A., 1077Davidson, N. E., 441, 805, 847Davies, P. J. A., 511

Davis, B. M., 1353

Davis, C. A., 1693, 1699Davis, P. L., 1571Davis, 1., 457

Day,R., 1129de Angebis, E., 601

de Anta, J. M., 1083Deb, N., 457, 1289

Dc Benedetti, V. M. G., 1767Debinski, W., 1743

DeBoer, G., 1499Debruyne, F. M. J., 1055Deeley, R., 773Degen, D., 1713

DeGiorgio, C. M., 619

de Giuli, R., 403Dehdashti, F., 933Deisseroth, A. B., 799deiong,J., 1123, 1717

Dekan, G., 1231

DeKoning. T. F., 1 143DeLap, R. J., 1475Dc Luca, A., 1239

deMagalhaes-Silverman, M., 434

DeMaria, D., 1685

DeMichele, M. A. A., 411de Murcia, G., I 163

Densmore, C. L., 1819

Depiseh, D., 1231Dermime, S., 593Deshane, J. S.. 1089deTakats, P. G., 659DeVictoria, C., 1981Devilder, M-C., 1673Dezso, B., 1543Diasio, R. B., 477

Dickson, R. B., 1207

di Isernia, G., 207

Dinareblo, C. A., 1341D’lncalci, M., 1123Dmitrovsky, E., 1077

Doglioni, C., 1591Domagala, W., 147Donehower, R. C., 541, 1921Donnelly, S., I 129Dorr, R. T., 947Dos Santos, B., 253Downey, G., 1285Dreyling, M. H., 1993

Drudis, T., 1843

Drum, P., 287

Dubois, J. S., 1341Duffy, M. J., 613Duigou, G., 1017, 1638

Dukowicz, A., 147

E

East Japan Paclitaxel StudyGroup, 941

Eastman, A., 791Ebert,A., 1879

Edwards, C. L., 837, 1285Eguchi, K., 553Ehring, B., 1427Eieher, S. A., 1659

Einhorn, L. H., 1063Ek, 0., 1533Elbendary, A. A., 1571

El-Deiry, W. S., 623, 1221Elder, E., 87Eller, S., 541Elliott, B., 773Ellis, A. L., 1489

Ellis, L. M., 1679

Ellis, W. J., 1039El-Naggar, A. K., 419, 903, 1553

Els#{228}sser, H-P., 1607Elson, P., 347Emadian, S. M., 1559

Emerson, D. L., 7Endo,Y., 1411

Engebstein. D., 1077Epstein, J. I., 389Epstein, M., 1341Ermak,G., 1251

Escobedo, A., 1887Eshleman, J. R., 1649Esposito, V., 1239

Estey, E., 799Etienne, M. C.. 507Evans, A. C.. Jr., 1571Evans, D. B., 2015

Evans, W., 1533

Fabbro, D., 1017, 1638

Fabra, A., 1887

Fagin, J. A., 1 19

Falette, N., 1439Faranda, A., 2007

Farr#{233},M., 13

Fearon, E. R., 1097Feierabend, C., 1299

Felsberg, G. J., 963Fenaux, P., 1031Fenoglio, C. J., 2015Ferguson, A. T., 805Fernandes, D. J., 1 107Ferrandina, G., 175Ferry, D. R., 659Fidler, I. J., 1627Fields, A. L., 1981

Figg, W. D., 483

Figge, J., 1251

Filipits, M., 1231

Filippa, D. A., 295

Fina, P., 1591

Finke, J., 347Finnegan, M. B., 837

Fisch, M. J., 1063

Fischer, P. H., 75Fisher, D. E., 435

Fisher, R. A., 897Fbechtenmacher, J., 21Fbeisher, M., 1819Fleming, R. A., 1107

Fojo, T., 1725

Fong, K. M., 1369

Fontanini, G., 1067, 1777

Forman, A., 837Fowber, S., 457, 1289Fox,S.B., 1191

Fracasso, P., 933Franeeschi, T., 1829

Franchi, A., 1801

Francis, D., 155

Frankel, A., 1307Fredericks, R. K., 963Freedman, R. S., 837, 1285

French, F. S., 889

Freytag, S. 0., 53Friedman, A. H., 963Friedman, H. S., 963

Fritsche, H. A., 419

Fuchs, I., 1879Fueger, R., 1285Fujie,T., 1619Fujinami, K., 929

Fujiuchi, S., 915

Fukuda, M., 553

Fults, D., 1559Fuqua, S. A. W., 1 199

Furihata, M., 1781

Furuya, Y., 389

Fusco, A., I 19

Fyfe, D. W., 659

Gacrama, P., 1285Galivan, J. H., 707Galli, J., 175, 1895

Gallick, G. E., 1397Gallie, B. L., 1499

Galbo, J. M., 549, 1685Gallo, 0., 261, 1577. 1801Gambacorti-Passenini, C., 593

Gan,J., 1951Gan, Y., 1275Gandhi, V., 653

Ganesan, 1. S., 303

Gansauge, F., 1469

Garand, R., 1673Garcia, E., 1439

Garner. R. C., 1795

Garnick, M. B., 295

Gasparini.G.. 1191

Gates, S. B., 1135Gazdar, A. F., I 185

Geissler, D., 1031

Genuardi, M., 1895

Gerald, W., 1361Gerken, S. C., 1559Gerl, A., 1565Gerson, S. L., 577, 1 129, 1353

Gerstmayer, B., 1001Ghosh, S., 1017, 1638

Ghoumari, A., 47Giantonio, B., 1685

Giavazzi, R., 1725, 1843

Giedlin, M. A., 669

Giesbreeht, E., 1499

Gill, G. M., 471

Gillies, S. D., 1951

Gimotty, P., 1901Giordano, A., 1239

Glaves, D., 1315

Gleason, M. J., 1931

Glennon, M. C., 981Goepfert, H., 903

Goh, H-S., 1049

Goldberg, G. L., 181, 1981Goldstein, R., 531

Goldwasser, F., 687Gollin, S. M., 641

Gonzalez de Leon, C., 837Gopabaknishna, R., 843

Gore, S. D., 1921Goris, M. L., 457, 1289

Gossett, L. S., I 135

Gottesman. M. M., 973Graham, M. L., 331Granchi, S., 1757

Grant, S., 1, 1915Grant, S. C., 1819Grassi, M., 601

Graubert, T. A.. 785Graves, D., 755

Greenberg, H., 1285

Greene, G., 1627Gregory,M.L.,SblGrem, J. L., 477Griem, K., 1453

Griffin, T., 287

Grillo-L#{243}pez, A., 457Grindey, G. B., I135

Grizzle, W. E., 1811Grochow, L. B., 1481Gr#{248}ndahl-Hansen, J., 155Groner, B.. 1001Groot, Y., 1717

Groshen, S., 1461Grossman, S. A., 541

Guarrasi, R., 207

Gubish, C. 1., 75

Clinical Cancer Research 2051

Guillot, C., 1439

Gundimeda, U., 843

Gunn, H., 347

Gunther, R., 1533

H

Haas, G. P., 1543

Habeck, L. L., 1 135

Haddad, G., 1499

Hafstrdm, L., 3 1 1

Hagmuller. E.. 21

Haider, K., I 231

Hall, S. H., 889

Hallman, J. D., II, 107Hamatake. M., 763

Hamide, J.. 1851

Hamil, K., 889

Hamilton, T. C., 549

Hamzavi, F., 1543

Han, N. M., 1397

Handschumacher, R. E., 1699

Hank, J. A., 319, 1951

Hara, I., 1837

Haraf, D. J., 755

Harezga, B., 147

Harousseau, J-L., 1673

Harrington, A. M., 1767

Harris, A. L., 303, 1191, 1591

Harris, C. C., 1767

Harrison, M. P., 331

Hartenstein, R., 1565

Hartman, N. R., 541, 953

Hartmann, L. C., 883, 1907

Harvey. H., 1215

Hasz, D. E., 721

Hattori, Y., 1373

Hatty, S., 1123

Hausheer, F. H.. 707

Hayashi, K., 1937

Hayashi, S., 1583

Hayashi, Y., 141 1

Hayes, J. S., 5 1 1

Heath, D., 311

Hedrick, L., 1097

Heelan, R. T., 1819

Heffelfinger, S. C., 1873

Heimer, M., 81

Heindl, L. M., 97

Heitjan, D. F., 1017, 1638

Helbe, S. I., 1515

Henderson, B. E., 743

Herath, J. F., 137

Herbst, H., 1879

Herndon, J. E., II, 963

Herold, M., 1031Herrmann, K., 447Hesdorffer, C., 873

Hess, K. R., 1489

Hessels, D.. 1055

Heston, W. D. W., 1445Heyman, R. A.. 51 1

Hickey. T. E., 277

Hieken, T. J., 1391

Hillman, G. G., 1543

Hilsenbeck, S. G., 585, 1199

Hinton, D. R., 619, 843

Hirabayashi, H., 127

Hirata, S., 915

Hirohashi, S., 1373

Hittelman, W. N., 1787

Hoffman, A. D., 1077

Hoflehner, E., 1031

Hohaus, S., 1895

HohI, R. J., 483

Hdhne, A., 1427

Homesley, H., I 107

Hong, W. K., 287, 855, 1787

Hord, M., 837

Horsfall, D. J., I 177

Horwitz, S. B., 1981

Hosaka, M., 929

Hosokawa, K., 1373

Houghton, A. N., 295, 679, 1837

Houghton, J. A., 107

Houghton, P. J., 107

Howard,C.M., 1239

Howard, K. L., 1063

Howard, S. P., 269

Howell, S., 3 1 1

Hozumi, N., 1417

Hsu, P. H., 883

Hu,S-X., 1169Hu,X.F.,7I3

Huang. P., 653

Huang. S., 1969

Huber, C., 11 15, 1427

Huff, V., 903

Hughes-Davies, L., 269

Hui, R., 923, 1177

Huland, E., I I 15

Hulme, M. J., 201

Hum, M., 69

Hungerford, J. L., 1499

Hunt, J. D., 75, 1851

Hurr, K., 903Hurr, K. G., 419

Husain, S. R., 1743

Huseby-Moore, K., 319

Hutchinson, J., 1453

Huynh, H., 2037

Hwang, E-S., 2029

Iglehart, J. D., 1571

Ikeda, T., 821

mo, y., 1373Inoue, A., 1781

Inoue, M., 2023

Irvin, J. D., 1533

Isaacs, J. T., 389

Ishida, T., 763

lshii, H., 1373

Ishikawa, H., 2023

Ishikawa, T., 1781

Issa, J-P. J., 805Itoh, H., 1373

Iwama, H., 1583

Iwasaki, Y., 929

Izquierdo, M. A., 1713

J

Jaeger, P., 1951

Jagannath, S., 947

Jam, R. K., 359

Jakubowski, A. A., 295

Jarvis, W. D.. 1, 1915

Jeffers, S., 1461

Jenkins, R. B., 137, 883, 1907

Jennings, T., I 251

Jett. J. R.. 1767

Johnson, B. E., 1103

Johnson, C., 947

Johnson, J. T., 127

Johnson, M. D., 1207

Johnson, P. C., 187

Johnson, S. W., 549

Johnston, A. L., 1685

Jones, J., 1981

Jones, P. A.. 743

Jordan, V. C., 223

K

Kahl, R., 1001

Kamen, B. A., 69, 331

Kanaya, T., 2023

Kanthanidis, P., 713

Kappler, K., 1341

Karbach, J., 641

Karp, D., 29

Kashimawo, S. A., 1017, 1638

Kasprzyk, P. G., 75

Kast, W. M., 1825

Kato, M., 1255

Katsaros, D., 201

Katsumata, N., 553

Katzenellenbogen, J. A., 933

Kaufmann, S. H., 847, 1921

Kavanagh, J. J., 837, 1285

Kawakubo, K., 1583

Keilholz, U., 767

Kelley, M. J., 1 103

Kemp, B. L., 419

Kennedy, M. J., 1481

Keohavong, P., 411

Kerbel, R. S., 1417

Kern, H. F., 1607

Kerr, B. M., 7Kerr, D. J., 659Kessler, M., 1 I 15

Khanna, C., 721

Khayat. D., 47, 1405

Khazaeli, M. B., 1811

Khil, M. S., 53

Khorsand, M., 319

Kida, Y.. 1369

Kidouchi, K.. 1937

Kiessling, R., 1825

Kikuchi, K., 915

Kilinski, L., 59

Killion, J. J., 1627

Kilpatrick, D., 549

Kim, E. E., 837

Kim, I. Y., 1255

Kim, J. H.. 53

Kim, S., 1017, 1543, 1638

Kim, S. H., 53

King, C. R., 75

Kingston, J. E., 1499

Kinsella, T. J., 981, 1299

Kirkwood, J. M., 29, 1 129, 1263

Kitadai, Y., 1679

Kitagawa, Y., 909

Kitajima, M., 909, 1155

Kitamura, M.. 821

Klassen, J., 773

Klausner, J. S., 721

Klein, L., 1509

Klempner, M. S., 1341

Klintmalm, G., 531

Knox, S. J.. 457. 1289Knuth, A., 641, 1427Kobayashi. T., 799

Kobayashi, Y., 749

Ko#{231},0. N., 1353Kohn, K. W., 687Kohorn, E. I., 1693

Koishihara, Y., 253

Kolesnick, R. N., I

Kondo, S., 821

Kono, K., 1825

Kopp, W. C., 501

Koren, G., 1499

Kornmann, M., 1469

Kotelnikov, V. M., 1453

Kozlowski, J. M., 1255

Krajewski, S., 389

Kramer, K.. 1361

Kris, M. G., 471, 1819

Knistjansen, P. E. G., 359

Krol,G., 1819

KrUger, A., 811

Kubo, Y., 915

Kubota, Y., 929

Kubushiro, K., 749

Kudelka, A. P., 837, 1285

Kuiper, C. M., 521

Kumada, K., 1937

Kumar,R., 1215Kunugi, K. A.. 981, 1299

Kuo, D. Y-S., 1981Kurie, J. M., 287, 1787

Kursar, J. D., I 135

Kyo, S., 2023

Kyritsis. A. P., 1931

Kyrtopoulos, S. A., 303

L

LaFollette, S.. 1453

Lah. T. T., 561Lai, P., 161

Lamerz, R., 1565Lampen, N. M., 1017, 1638

Lamph,W.W.,511

Land, V. J., 331

Landreneau, R. J., 41 1

Lang, S., 1255

Langdon, S. P., 201

Lange. P. H., 1039

Langton-Webster, B. C., 207

Lapidus. R. G., 805

Larson, L. V., 477

Larson, M., 29

Lattime, E. C., 1383

Laub, P. B., 1685

Lauriola, L., 1895

Law, R. E.. 619, 843

Lazo, S., 493

Leach, S. D., 2015

Lebkowski, J., 59

Lechago,J., 1151

Lechago, L. V., 1151

Ledakis, P., 561

Leder. G. H.. 1469

Lee, C., 1255Lee,C.S.L., 1177Lee, J-H., 2029Lee, J. J., 1787, 2015

Lee, J. S., 287, 1 103, 1787Leek, R., 1591

2052 Author Index

Lehnert, M., 403

Leichman, C. G., 1461

Leiehman, L., 1461

Lengyel, E., 1879Leone, R., 1829LeRiche, J., I 103

LeSauteur, L., 1361

Lesser, G. J., 541

Leveille-Webster, C. R., 695

Leventhab, B. G., 331

Levin, B., 37

Levin, V. A., 1931

Levy, R., 457

Ley, T. J., 785

Li, C-W., 339

Li,J., 1169, 1619

Li,L.H., 1143

Li, Y., 107

Liang, B., 483

Liang, J. C., 1553

Liang, M. D., 477Lidereau, R., 1 163

Lieber, M. M., 137

Liles, T-M., 457

Lim, P. C., 1907

Lin, F., 1867

Lin, S., 1445Lin, W-e., 127

Lin, Y., 929

Lindemann, M. J., 669

Lindn#{233}r,P., 31 1

Lindstrom, M. J., 981, 1299

Ling, V., 1499

Link, K. H., 1469

Lippman, S. M., 287, 1787

Lipton, A., 1215Lissner, R., I I 15

Litwin, S., 1895Liu, L., 577, 865, 1129

Liu,T., 1811

Liu, T-J., 1659

Livingston, P. 0., 679Lloveras, B., 1887

Lloyd, T. L., 7

LoBuglio, A. F., 1811Loewen, G. M., 669

Loewen, G. R., 471Logan, T. F., 1263Loggie, B. W., I 107

Lokiec, F., 1943

Longo, D. L., 501

L#{248}nning, P. E., 1515Lopez, M. P., 1083Lorber, M. I., 1699

Lorenz, J., I 1 15Lotan, D., 855Lotan, R., 855, 1659

Lotze, M. T., 87, 127, 641

Loughlin, S., 1489

Low, J. A., 1207Lower, E., 1873Loyer, E., 1285

Lu,C., 1417Lu, Z-H., 477Luechi, M., 1067

Ludi, C. W., 97

Luna, M. A., 903

Lundgren, S., 1515

Luo, X., 107Lutz, L., 107Lyerly, H. K., 59

M

Madden, T., 1489

Maeurer, M. J., 87, 641

Maggi, M., 1757

Magliubo, G., 601

Mai, M., 1679

Malkhandi, J., 659

Malliek, S., 1981

Mandal, M., 1215Mann, K., 1565

Manni, A., 1901

Mantovani, G., 161

Manzano, R. G., 1321Marehesi, E., 593

Marchetti, A., 1591

Markiewski, M., 147

Markowitz, S. D., 1639, 1649Marks, J. R., 1571

Marquez, C., 457, 1289Marras, S. A. E., 1055Marshall, J. L., 1475

Martelli,M.L., 119

Martin, D., 87, 641

Martinec, J., 1509

MartInez-Miralles, E., 13

Marubini, E., 1 191

Marverti, G., 991Masri, L., 619

Massimini, G., 287

Mastrangebo, M. J., I 383Masuoka, K., 1383

Matsui, H., 915

Matsumoto, T., 821

Mauger, D., 1901

Maughan, R. L., 1543

Maurel, J., 1083

Maurizi, M., 1895May, F., 1445Mazzarella, G., 1239MeCaffery, M., 679

MeCaul, K., 1177MeClelland, R. A., 923MeCloskey, D. E., 441, 847

MeCue, P., 1383McDonald, J. D., 1559

McDonnell, 1. J., 1999McGinn, C. J., 1299MeGovren, J. P., 1 143MeLain, D., 347

MeLendon, R. E., 963

Mebacrinos, A. C., 41 1

Melief, C. J. M., 1825

M#{233}nard,S., 1777Mendelsohn, J., 601

Mendebsohn, L. G., 1135

Mera, R., 1851

Meredith, R. F., 1811

Meropol, N. J., 669Messinger, Y., 1533

Meyers, R., 947

Meyn, R. E., 1665

Mick, R., 755

Mier, J. W., 1341

Mikhail, M. S., 181

Milano, G., 507

Miller, A., 865

Miller, C. B., 1921

Miller, M. A., 1873

Miller, R. D., 1767

Miller, V. A., 471, 1819

Miller, W. R., 201

Mills, G. B., 1307

Milpied, N., 1673

Minami, H., 43

Minderman, H., 369, 1961

Mitchell, K., 303

Mitsudomi,T., 763, 1185

Miyamoto, H., 929

Miyazono, K., 1255

Miyokawa, N., 915

Mizokami, M., 1937

Mohler, J. L., 889

M#{246}hler,T., 767

Moisan, J-P., 1673

Monegier du Sorbier, B., 1943

Montag, A., 755

Montecillo, E. J., 1543

Montgomery, E. A., 1859

Monz#{243},M., 1083Morelbi, D., 207

Morelli, L., 1591

Moreno, A., 1887

Moreno, I., 1083

Mon. M., 1619

Mori,T., 821

Morice, R. C., 1787

Moritz, D., 1001Morris, R., 1107

Mortimer, J. E., 933

Motzer, R. J., 1077Mouawad, R., 47, 1405Mouridsen, H. T., 223

Mueller, M., 1017, 1638

Mues, G., 531

Muggia. F. M., 1461

Mukherjee, B., 1445Mullen, C. A., 53

Mundle, S., 1453

Murphy-Boesch, J., 339Murray, C., 493

Murray, M. K., 1315

Murray, N., 1103

Murugesh, D., 59

Musgrove, E. A., 923

Muss, H. B., I 107

Mussi, A., 1067

Myers, C. E., 483

Myers, D. E., 1533

Myers, J. N., 127

N

Naftzger, C., 1837

Nagel, M., 21

Nair, M. G., 707

Nakagawa, K., 1103

Nakagawara, A., 1097

Nanus, D. M., 1077

Naor,D.,81l

Naredi,P., 311

Negendank, W. G., 339

Negrin, R., 457

Nelson, J. B., 379

Nelson, W. G., 379

Nemeth, J. A., 1255

Neri, G., 175, 1895

Newkirk, K., I 859

Newlands, E. S., 897

Newman, R. A., 1489

Nguyen, D., 1665

Nicholson, R. I., 923

Nicholson, S. K., 897Nickerson, T., 2037

Nicobetti, M. I., 1725

Ning, S., 1289

Ning, S-C., 457

Nishida, K., I 185

Nishimura, T., 1859

Nishiwaki, Y., 941

Nodzenski, E., 755

Noordhuis, P., 1327Norman, S. A., 187

Normanno, N., 601

Noviello, C., 1601

Nozawa, S., 749

Nussler, V., 1031

0

Obasaju, C. K., 549

Obini, N. I.. 1743

O’Brien, J. M., 1499

Ochiai, A., 1373

Ockert, D.. 21

Oda,M., 1411

O’Dwyer, P. J., 339, 549, 1685

Oefelein, M. G., 1255

Oelkuct, M., 75

Oesterreich, S., 1 199

Ogami. A., 1185

Ogoshi, S., 1781Ohe, Y., 553Ohsaki, Y., 915

Ohsugi, Y., 253

Ohta,Y., 1411

Ohtsuki, Y., 1781

Ohyashiki, J. H., 1583

Ohyashiki, K., 1583

Okamoto, A., 821

Olencki, T., 347

Olopade, 0. 1.. 1993

Oppenheim, J. J., 501

O’Reilly, S., 541, 953

Oridate, N., 855

Onto, E., 1937

Orlando, C.. 1757

Ortiz, V., 1713

Osaki,T., 1185

Osborn, M., 147

Osborne, C. K., 585, 1 199

Oshita, F., 553

#{216}sterlind, K., 155

Ottaviano, Y. L., 805

Oyama. T., I 185

Ozawa, S., 909, 1155Ozols, R. F., 549

Ozturk, M., 1439

P

Pacini, F., 1777

Padavic-Shaller, K. A., 339

Pagani, A., 1757

Pagani, 0., 1 123

Pairolero, P., 1767

Paladugu, A., 1993

Palan, P. R., 181

Paleologos, N., 963

Palmer, J. L., 1553

Panje, W., 1453

Pantel, K., 1879Papandreou, C. N., 1077

Clinical Cancer Research 2053

Pappot. H., 155

Paradinas, F. J., 897

Park, S. J., 269Park. W., 2029Parkin, J. D., 713

Parl, F. F., 805Parmiani, G.. 593

Pastan, I., 245, 973, 1523

Pathak, S., 1627

Pati, R., 707

Patronas, N.. 483

Pavanel, F., 1829

Pawlita, M., 767

Pazdur, R., 37, 227

Pazzagli. M.. 1757

Pegram, C. N.. 963

Peinado, M. A.. 1887

Pepe, S., 207Perez, R. P., 669Pen, A., 1757

Persons. D. L.. 883

Peschel,C.. 1115

Peters, G. J., 521, 1327

Peters, W. P., 81

Petersson, M., I 825

Pettaway, C. A., 1627

Pfister, D. G.. 1819

Philip, M., 59

Philip. P. A., 303

Philip. R.. 59

Piatyszek, M. A., 799

Pierceall. W. E., 1097

Pifarr#{233},A., 1083

Piblasch, J.. 1469

Pinedo. H. M., 1327

Pinkel. D. P.. 331

Pinto, J. T., 1445Pioli. P., 873

Pirker, R., 1231

Pisters, K. M. W., 1819

Pitelli, M. R., 1843

Plott,W.E., 1811Plowman, J., 1 143Plunkett. W.. 653, 1731Podratz, K. C., 1907Pogliani, E., 593

Pollak, M., 2037Pollina, L., 1777

Pommier, Y., 687

Pontes, J. E., 1543Porfirio, B., 1577

Porter, M., 669Potkul, R. K., 1825Prabhu, N. S.. 1221

Prasanna, P., 865

Preisler, H. D., 1453

Press, M. F., 743

Prestigiacomo, L. J., 847

Price, B. D., 269

Pritze, W., I 879

Pu, Q., 843

Pugh, M.. 29Puisieux. A., 1439Pullen, D. J., 331Pun, R. K., 1743

Qian. M., 1685

Qian, Z., 1851

Qiao.C.H., 1445

R

Raber, M. N., 1489

Rabinowich, H., 161, 1263

Rager. H. C.. 501

Raghavan. D.. 1315

Rak, J. W., 1417Ramage. A. D.. 201Ramirez. E.. 1627

Rapp. M-J.. 1673Rasmussen, A. A.. 1859

Ratain, M. J., 43

Ravagnani, F., 593

Rayman. P.. 347

Raymond. E.. 1713

Real, F. X., 13Reale, M. A., 1097Redovan, C., 347Reed, E.. 483Reed, J. C.. 389Reichert, T. E., 1263

Reid, I. N., 1795

Reilly. D., 1685

Reiman, R.. 963

Reisfeld, R. A., 1951

Reiss, R., 873

Reiter, Y., 245

Ren#{233}e,N., 507Ressing. M. E., 1825

Resta, D., 347

Reyes-Mugica, M., 1097

Richards, F., I 107

Richardson. C.. 873

Richelme. H.. 507

Richmond, E., 1475

Rieppi. M., 1725

Rigas. J. R.. 471, 1819

Rim, P., 1867

Ritz, J., 493Rixe, 0., 47, 1405Ro, J. Y., I103, 1787

Robertson, J. F. R.. 923

Robinson, R. A., 883

Roeha,M., 811Roche, P. C., 1907

Roddey, G.. 1999

Roe, D. J., 947Rogatko, A., 549Rogers, E., 635

Rollinger-Holzinger. I.. 1031

Romero-Fisehmann, D.. 561

Romney. S. L., 181

Ronayne. L.. 1341

Rose, D. P., 1751

R#{246}sel,M., 447

Rosell, R.. 13. 1083Rosenberg. N., 561

Ross, R. K., 743

Roth. J. A., 1659, 1665Rowinsky. E. K.. 541. 953, 1921

Rubinstein, M. C.. 1097

Ruggiero, A., 207

Ruiz van Haperen. V. W. T., 521

Runowiez, C. D., 181, 1981

Rusinkiewiez, J., 1285

Russell, C. D., 181 1

Russell, G. B., 1107

Rustin, 0. J. S., 897

Rustum, Y. M., 369, 707. 1327,

1961

S

Saal, J.. 1289Saeger, H-D.. 21

Saijo. N., 553, 941

Sakamoto, H., 1373

Sakayori. M.. 749

Salisbury. A.. 303

Salomon, D. S., 601

Salter, R., 641

Salvadori, B.. 2007

Salwen, S.. 1383Samid, D., 483, 865

Samoszuk, M., 1867

Samuels, B.. 1509

Sanchez, J. J., 1083

Sanderink, G-J., 1943

Sandoval, A., 1731

Sandstrom, K., 347

Santoro, M., 119

Santucci, M., 1801

Sar, M., 889

Saragovi, H. U., 1361

Sartorius, S. E., 1921

Sasaki,T., 1411

Sato. T.. 1383Sausville, E. A., 1705

Scambia, G., 175

Seardino. P. T., 399, 635Schadendorf, D., 447

Schalken, J. A., 1055

Schaller, G., 1879

Scheck, A. C., 187

Scheibenbogen, C., 767

Scheper. R. J., 369Scherf, U.. 1523

Schieren, I.. 1017, 1638Schiff, P. B., 1017, 1638

Schiller, J. H.. 29, 319Schirrmaeher, V., 21, 811

Schlom,J., 1811Schmier, J. W., 767

Schneider, M., 447

Schnierle, B. S., l0()l

Schold, S. C., Jr., 963

Schroeder, L., 1509

Schwartz, P. E.. 1693, 1699

Schwulera, U.. I 115

Scoppa. C. A.. 75

Seelig. S. A.. 883

Seiter, S., 447Sekine. I., 941

Seliger, B., 1427

Selvam, M. P., 601Sengupta. S., 773

Serio, M., 1757

Seshadri, R., I 177

Sessa, C.. 1 123. 1717

Sessions, R. B.. 1859

Sestini, R., 1757

Seymour, J. F.. 653

Sgagias. M. K.. 215. 827

Shack, S., 865Shackelford, K. A., 1 135Shalinsky. D. R., S I I

Shapiro, C., 493

Shapiro, J. R., 187Shapiro, L., 1341

Shaw,E.G., 1103

Shaw, J. W., 1255Shay. J. W., 799

Sheehan, C., 1417

Shen, H-J., 1981Shen, Y., 1999

Sherman, M. L., 295Shibata, A., 743

Shih, C., I 135

Shih, I-M., 569

Shillitoe. E. J., 1659

Shimamoto, T., 1583

Shimamura, A.. 435

Shimizu, J., 141 1

Shimizu, N.. 909

Shin, H. J. C.. 1787Shinkai, T., 553

Shinozaki, H., 1 155

Shipley, L. A.. 359Shuster, J. J., 331Siegal, G. P.. 1089Siegel. B. A., 933

Siegfried. J. M., 75, 411Sierra, A., 1887

Silber, J. R., 735

Silvestrini, R., 2007Simonetti, L., 261, 1577

Simons, J. W., 379

Simpson, B. J. B., 201

Singletary. S. E., 419Sinierope, F. A.. 37, 1999. 2015

Sirotnak, F. M., 1819Skenderis, B. S., II, 1961Skibber, J. M.. 1665

Skrepnik. N., 1851

Slater, A., 713

Sledge. G. W.. 1063Slovak, M. L., 369, 1961Smid, K., 1327Smith, A., 69, 659

Smith, D. C., I 129

Smith, D. R., 1049Smith, H. S., 805

Smith, J. W., II, 501

Smith, P. J., 1369

Smith, S., I 107

Sneige. N.. 419Soiffer, R. J., 493

Sondel, P. M., 319, 1951Song. K.. 1335

Sonobe, H.. 1781

Sorce, D.. 1341Sorich, M., 59Soubrane, C., 47, 1405Souliotis, V. L.. 303

Sperotto. L.. 1829Spicer. D.. 1461

Spitz, F. R., 1665

Staib, L., 1469

Stambrook, P. J.. 1639

Stapleton. A. M. F.. 399, 635Steek, K., 419Steekelman, E., 1077

Stephens. L. C., 1999

Sterns, E.. 773Stetler-Stevenson, M. A., 1705Steuber, P., 331Stoelben, E., 21

Stone, M. J., 531, 1705Storer, B., 319Storkus, W. J., 87, 641

Storm, H. H., 223Storthz, K. A., 1659

Stower, M. J., 1795

2054 Author Index

Strathearn, G., 1867

Strong, J. M., 541, 953, 1481

Struck, R. F., 541Struff,W.G., 1115Su, D., 531Suchomel, R. W., 1231Suffoletto, B. P., 1445Sugarman, S. M., 1489Sugimachi, K., 763, 1 185

Sugimura, T., 1373

Sugio, K., 1185

Sullivan, 1. L., 75Sumi, S., 1937Suminami, Y., 127Sun, X., 1335Surfus, J. E., 1951

Surnock, A. A., 619Sutherland, R. L., 923, 1 177Suzuki, H., 821Swaney, W., 641

Sweatt, W. H., 379

T

TactIc, R., 253Tagliafem. P., 207Takahashi, S., 137

Takahashi, Y., 1679Takechi, Y., 1837Taketani, Y., 427Takimoto, C. H., 477

Tamp#{233},R., 1427Tamura, 1., 553Tanaka, M., 1411

Taniguchi, 1., 821

Tao, Y., 295Tarabobetti, G., 1725, 1843

Tates, A. D., 303Taylor, S., IV, 1453Tazelaar, H., 1767

Templeton, M. A., 295Terada, M., 1155, 1373Tester, D., 1907Tester, W. T., 561Thaler, H., 295Theiblet, C., 1601Thibault, A., 483, 865Thibodeau, S. N., 1907Thiessen, J. J., 1499Thomas, M. P., 287

Thomazy, V., 511

Thompson, C. B., 1215Thompson, T. C., 399, 635lien, R. D., 963

lilgen, W., 447

Tillery, G. W., 531lilley, W. D., 277limme, I. L., 399, 635loi, M., 821lomasic, G., 2007lomida, A., 427lominaga, I., 821Tompkins, A. C., 483Tong, A. W., 531Tong, W. P., 471, 1445, 1819

lorres, R., 687l#{243}rtola,S., 1887

lortora, G., 207, 601

16th, K., 369, 1961

louroutogbou, N., 227loyama, K., 1583loyoshima, E., 915

Trapasso, F., 1 19

Irehu, E. G., 1341

Irepel, J., 483Iresukosol, D., 837Inicarico, C., 1757

Iricot, G., 947

Trisber, K., 457, 1289

Irivers, G. E., 1767

Irock, B. J., 1859Troncoso, P., 1553Trovati, M., 261True, L. D., 1039

Iruglia, J. A., 471Irujillo, Y., 1509

Trump, D. L., I 129Truong, L. D., 399, 635

Tsai, Y. C., 743

Tseng, S. H., 735

Isukazaki, K., 749

Tsuruo, I., 427

Isuruta, H., 1155Isuruta, K., 821

lu,Z.N.,419Tuason, L., 347Tubbs, R., 347luck, A., 773Tucker, M. A., 1103lutsch, K. D., 1299Twentyman. P. R., 403, 1321lyer, C. L., 81Tyson, L. B., 1819

U

Uchino, S., 1373Uckun, F. M., 1533Ueda,M., 909, 1155

Ueda, R., 1937

Uemura, H., 929

Ueno, H., 2023Ueo, H., 1619

Uhr, J. W., 1705

Ullrich, S. E., 1969Ulm,E.H.,47lUmansky, V., 81 1

Urba, W. J., 501Urzi, G., 873

V

Vadell-Nadal, C., I 3

Vaickus, L., 669

Vabdimarsson, G., 1231Valenti, M., 687van Debft, J. H. M., 303van der Pod, H. G., 1055

van der Wilt, C. L., 1327

Vanhoefer, U., 369, 1961

van Laar, J. A. M., 1327

van Tellingen, 0.. 1717

Varma, D., 837Vams, C., 457

Veerman,G.,521

Venzon, D. J., 483Verderio, P.. 1 191

Vergani, V., 1843

Verjee, Z., 1499

Verola, 0., 47

Veronese, S., 1591

Veronesi, U., 2007

Verret, A. L., 471Verschraegen, C. F., 837

Verweij, J., 43

Vesole, D. H., 947

Vessella, R. L., 1039

Vet, J. A. M., 1055Viale, G., 1843

Vick, N. A., 963

Vignati, S.. 1067

Visconti, R., 1 19

Vitetta, E. S., 1705Voeltzel, I., 1439

Vokes, E. E., 755

von Hoegen. P.. 811Von Hoff, D. D., 1713Vredenburgh. J. J., 81

w

Wada, Y., 1937Waldman, I., 1221Wall, D. M., 713Wanders, J., 1717Wang, H., 1993Wang, P., 47Wang,R-Y., 1553Wang. T-L., 569Ward, M., 873Warrell, R. P., Jr., 471

Watanabe, K., 941Watanabe, Y., 141 1Waud, W. R., 1 143Webber, K. 0., 1523Weber, C., 287Weichselbaum, R. R., 755Weil, M., 1405Weiner, L. P., 619Weinstein, I. B., 1017, 1638

Weiss, M. H., 619, 843

Weitzel, H., 1879

Weitzman, S. A., 805Welch, M. J., 933Wels, W., 1001Wereley, J. P., 1009

Wesly, 0., 319Westra, W. H., 569Weyant. R. J., 41 1Wheeler, R. H., 1811

Wheeler, I. M., 399, 635

Whitehead, V. M., 331

Whiteside, I. L., 127, 161, 1263

Wientjes, M. G., 1275Wikstrand, C. J., 963

Wilding. 0.. 319, 1299

Wilhelm, K., 1115Wilkes, K. A.. 669

Willhauck, M., 767Williams, L., 295, 679

Williams, R. H., 635

Wilmanns, W., 1565

Wilson, E. M., 889

Wilson, M. R., 1627

Winick, N. J., 69

Winn, R., 128S

Wissel, P. 5., 7

Witherspoon, S. M.. 7

Witjes, J. A., 1055

Wolff, I.. 1717

Wong. J. R., 1335Wood, N., 1453

Worzalla, J. F., I 135

Woster, P. M.. 441

Wright, K. A., 1321

Wright. W. E., 799

Wu, E. Y., 1685Wu, 0. 5., 623, 1221Wu, X., 1461

x

Xie, K., 1969Xu, H., 1851

Xu,H-J., 1169Xu, X., 1795Xu, X-C., 855Xu, Y., 1837

V

Yamada, M., 427Yamaguchi. N., 1373

Yamamoto, N., 553Yamamoto, Y., 821Yanagihara, K., 1373

Yang, B., 1639, 1649Yang, G., 399, 635

Yang. J.. 441

Yang, X., 2037Yang. Y., 1619Yanishevski, Y., 1533

Yao, T-J., 679Yassin, R., 1873

Yasumoto, K.. 1 185Yasumura, S., 127

Yau, J., 59Yoneda, S., 941

Yoshida, M., 821

Yoshikawa, C.. 1781

Yoshikawa, H., 427

Younes, M., 1151

Yu, R., 1787Yung, W. K. A.. 1931

z

Zaidi, N. H., 577

Zalcberg. J. R.. 713

Zabutsky, M. R., 963

Zaninelli, M., 1829

Zelner, D. J., 1255Zeng, Y-X., 1221Zhang, L., I 19

Zhang, R., 477Zhang, W., 799, 843

Zhao, X. G., 963Ziesmer, S. C., 1907

Zimmerman, P. V., 1369

Zdller, M., 447Zwelling, L. A., 1489

Zwierzina, H., 1031

Vol. 2. 2055-2072, December /996 Clinical Cancer Research 2055

SUBJECT INDEX

Volume 2

A

Acroleinmultidrug resistance protein

modification, 1321

Adenocarcinoma, colonirinotecan combined with 5-tluorouracil

or etoposide, xenograft models, I 07

Adenocarcinoma, pancreaticresectable

bcl-2 and p53 expression, 2015

Adenovirusp21

truncated, growth suppression, I 221

wild-type p53. radiation sensitization,

I665

Adhesion moleculesCD8� I cells

GM-CSF release, melanoma T-cell

epitope detection and, 87

CD2O�#{176}Y-labeled anti-CD2O mAb,

recurrent B-cell lymphoma therapy.

457

CD44

expression, pancreatic carcinoma,

I 607

mRNA isoforms. thyroid and breast

carcinoma, I 251

variant isoforms. malignant

melanoma, 447expression, lymphoma liver metastasis,

811

5’-AdThd: see 5’-Amino-S’-deoxythymidine

Aerosol deliveryinterleukin 2 liposomes. canine studies,

721

natural IL-2, pulmonary malignancy,

I I 15

AG331continuous infusion, phase I trial, 1685

06-Alkylguanine-DNA alkyltransferasemodulation by carmustine and

streptozocin, refractory melanoma,

I 129

Alkyltransferasequantitative immunohistochemistry.

malignant colon. 577

retroviral gene transfer, human

hematopoietie progenitors. 13S3

ALRT1OS7combined with cisplatin

antitumor effects, human oral

squamous carcinoma xenografts, S I I

9-Aminocamptothecincisplatin cytotoxicity potentiation, 687

5’-Amino-S’-deoxythymidineIdUrd metabolism modulation, colon

cancer xenografts. 981

Aminopterinleukemia treatment, 69

Androgenreceptors

gene mutations, prostate cancer. 277

prostatic hyperplasia and carcinoma,

889

Aneuploidybreast carcinoma, 883

Aneusomychromosome-specific

breast carcinoma, 883

prognostic significance. prostate

carcinoma, 137

Angiogenesisdetermination

and estrogen receptor status. node-

positive breast cancer. 1 191

inhibition by IL-b, melanoma, 1969

inhibition by paclitaxeb. 1843

intestinal-type gastric carcinoma, I 679

Anthracyclinebifunctional chemotherapy with

nitrosourea, bladder cancer, I 315

MDRI expressionupregulation prevention by

cyclosporine A and PSC 833, 713

Antibody: see also Monoclonal antibodyanti-GD2-1L2 fusion protein

effector cell activation, 1951

anti-p53

serum, predating cancer, I 767

antireceptor

combined with retinoids, myeboma,

253

dual therapy with interferon, metastatic

colorectal cancer, I 8 1 1

engineering

recombinant Fv immunotoxins, 245

Antigen-expressing cells

TNF-B I (Fv) fusion protein cytotoxicantitumor activity. 1523

HLA-Abmelanoma T-cell epitopes. detection,

87

HLA-A2melanoma loss, 641

proliferating cell nuclear

and occult neck metastases, laryngeal

carcinoma. 1801

truncated p21 adenovirus, growth

suppression, 1221

prostate-specific

-producing prostatic carcinoma

xenograft LuCaP 23. 1039

prostate-specific membrane

folate hydrolase, prostatie carcinoma

cells. 1445

transporters associated with processing

MHC class I and, renal cellcarcinoma, 1427

tumor

gene expression. gastric carcinoma,

1619Antisense oligonucleotides

anti-EGF-related growth factorgrowth inhibition, colon carcinoma,

601c-mvc blockade, thyroid carcinogenesis,

1 19

Apoptosisand chemosensitivity, tumor cells, 623

coloreetal tumorigenesis. I 999

induction

ATRA and 4HPR. head and necksquamous cell carcinoma cell lines,

855

ceramide and, Iphenylbutyrate. prostate cancer. 379

loss, ductal breast carcinoma, 1887

modulation by HER2 overexpression.

MCF-7 cells, 1215modulation by PKC signal transduction

pathway, 1915

AR209

effects on orthotopic human lung

cancer, 1851

Arabinosylcyosine: see CytarabineArea under the concentration-time

curve

total topotecan, limited sampling model,

43

Aromatic fatty acidsmultidrug resistance vulnerability, 865

ATRA: see all-trans-Retinoic acidAUC curve: see Area under the

concentration-time curveAutologous tumor cell vaccine

Newcastle disease virus-infected

active specific immunotherapy.

colorectal carcinoma, 21

Autotransplantshigh-dose melphalan. renal failure, 947

Axillary lymph nodes-negative breast cancer

hsp27, 1199

Ki-67 vs S-phase fraction. 585

BAGE

B

expression, gastric carcinoma, 1619

Batimastatgrowth inhibition, solid breast tumors,

I 207BB-94: see

B cellschronic lymphocytie leukemia

chromosome l3qb4 deletions, 1673

lymphoma

recurrent. �#{176}Y-labeled anti-CD2OmAb therapy, 457

precursor, leukemia

B43-PAP plus cytosine arabinosidetreatment, SCID mice, 1533

bcl-2 proteinexpression

non-small cell lung cancer, 915

prostatie cancer, 389

reseetable pancreatic adenocarcinoma,

2015

T� breast cancer. 1887

-induced apoptosis

modulation by HER2 overexpression.

MCF-7 cells, 1215prognostic significance

2056 Subject Index

early stage head and neck cancer afterradiotherapy, 261non-small cell lung carcinoma, 1067

bcl-XL protein-induced apoptosis

modulation by HER2 overexpression,MCF-7 cells, 1215

BCNU: see CarmustineBEC2

anti-idiotypic vaccine

immunization, melanoma, 679Bile

irinotecan metabolites, 1943Bioassay

P-glycoprotein inhibition, serum, 403Biological agents

metastatic melanoma, phase I study, 295Biomarkers

p53 mutations, multifocal transitional

cell carcinoma of bladder, 1795

Bisantrenehematotoxicity

bisantrene resistance, retroviral MDRIgene transfer, 973

Bizelesinantitumor activity. mice. I 143

Bladder carcinomachemotherapy

bifunctional anthracycline and

nitrosourea, I 315

p53 mutations, 1055telomerase activity, 929transitional cell

multifocal, molecular screening withp53 mutations, 1795

Bladder tumorsdoxorubicin pharmacodynamics. 1275

Bladder washingsp53 mutations analysis, 1055

Bleomycinresistance

cytokeratin expression and, 97Blood: see Peripheral blood; Whole

blood

Blood vessels

tumorcounts, intestinal-type gastric cancer,1679eosinophil peroxidase, 1867

Bone marrowbisantrene resistance, retroviral MDR1

gene transfer, 973B43-PAP

combined with cytosine arabinoside,B-cell precursor leukemia, 1533

Brain tumors

methylator resistanceMGMT and, 735

resection cavities with subarachnoid

communication

intrathecab ‘311-labeled 8lC6 mAbtherapy, phase I trial, 963

Breastepithelial cells

lymphokine-activated killingsensitivity, 207

proliferative disease

vascularity. 1873Breast carcinoma

aneupboidy, 883

apoptosis modulation by HER2

overexpression, I 215bilateral, cbonal analysis, 743

CD44 mRNA isoforms, 1251cell death

paclitaxel-induced. 847

chromosome 6q loss of heterozygosity,1601

cyclin Dl and estrogen receptor mRNA

levels, 923DNA/RNA content, flow cytometric

analysis, 419

ductalapoptosis loss, I 887

estrogen receptor status

FES-PET and, 933

mRNA levels, 923immunomagnetic purging from

peripheral blood progenitor cells, 81

immunotherapy

active, gene modification of tumor

cells, 59

interleukin 6 paracrine growth factor,215

keratin 18 protein expression. 1879

MRP and MDRI expression, 1231

node-negative

hsp27, 1199

Ki-67 vs S-phase fraction, 585p53 expression, prognostic value,2007

node-positive

adjuvant tamoxifen, predictors ofoutcome, 1191treatment failure, Her2/neu

overexpression, 1509omega-3 fatty acid suppressive effects,

17�1pl6m�4” expression, 1993

�J9ARF expression, 1993PARP expression and genomie

instability, 1163

PDGF-�3 receptor, 773

positron emission tomography, 933postmenopausal

plasma estrogen and megestrolacetate, 1515

prognostic markers

cathepsin D. 613cyclin Dl gene amplification, 1 177

Ki-67 vs S-phase fraction, 585

MIB-1 tumor cell proliferation rate,

147

ornithine decarboxylase, 1901

p21 expression, 1591p53 expression, 1591

p53 expression, validation, 2007

urokinase plasminogen activator, 613RNA content, biological significance,

419systemic therapy response. PET and,

933

lymph node metastases, 1887lGF-�3, secretion

stimulation by INF-a, 827

treatment failure

Her2/neu overexpression, I 509

Breast carcinoma in situpreinvasive vascularity, I 873

Breast tumors

ER and PR gene methylation, 805

growth inhibition by batimastat. mice,

1207

Bronchial epitheliummetaplastie

EGFr expression. I 787D,L-Buthionine-(S,R)-sulfoximine

and multidrug resistance protein

function. 1961

C

E-Cadherinand occult neck metastases, laryngeal

carcinoma, 1801

Cancer: see CarcinomaCanthaxanthin

plasma levels, cervical intraepithelial

neoplasia and cancer, I 81

Carboplatincombined with cyclosporine A

refractory gynecologie cancer, phase I

trial, 1699refractory ovarian and fallopian tube

cancer, phase II trial, 1693

combined with paclitaxel.

pharmacokineties, 549

platinum-DNA adducts, ICP-MS

quantitation in peripheral blood

leukocytes. 1829

Carcinomaadvanced

combined leucovorin-fluorouracil and

iododeoxyuridine. 1475

high-dose edatrexate with oral

leucovorin, phase I trial, 1819PALA combined with fluorouraciland dipyridamole, phase I study, 1 107

9-cis retinoic acid, phase I trial, 471

choriocarcinoma

tebomerase activity. 2023

cisplatin resistance

thioredoxin, 427

interleukin 1 receptor antagonist

induction after IL-I therapy. 501

lovastatin, phase I study. 483

metastatie

interleukin-2 effects on natural killer

cells, 493

serum anti-p53 antibodies predating,

I 767

Te activity, mitoehondria, I 335TNF-B1(Fv) fusion protein antitumor

activity. 1523

Carcinoma, bladderchemotherapy

bifunctional anthracycline and

nitrosourea, I 315

p53 mutations. 1055

telomerase activity, 929Carcinoma, breast

aneuploidy, 883

apoptosis modulation by HER2

overexpression, 1215

bilateral, clonal analysis. 743

CD44 mRNA isoforms, 1251cell death

paclitaxel-induced, 847

chromosome 6q loss of heterozygosity,

1601

Clinical Cancer Research 2057

cyclin DI and estrogen receptor mRNA

levels, 923

DNA/RNA content, flow cytometrieanalysis. 419

estrogen receptor status

FES-PET and, 933

mRNA levels, 923

immunomagnetic purging from

peripheral blood progenitor cells, 81

immunotherapy

active, gene modification of tumor

cells, 59

interleukin 6 paracrine growth factor,

215

keratin 18 protein expression, 1879

MRP and MDRJ expression, 1231

node-negative

hsp27, 1199

Ki-67 vs S-phase fraction, 585

p53 expression, prognostic value.

2007

node-positive

adjuvant tamoxifen, predictors of

outcome, 1191

treatment failure, Her2/neuoverexpression, I 509

omega-3 fatty acid suppressive effects,

I 751

pj61N1(4�� expression, 1993

p/9ARF expression, 1993

PARP expression and genomic

instability, 1163

PDGF43 receptor, 773postmenopausal

plasma estrogen and megestrol

acetate, 1515

prognostic markers

cathepsin D, 613

cyclin Dl gene amplification, 1 177

Ki-67 vs S-phase fraction. 585

MIB-l tumor cell proliferation rate,147

ornithine decarboxylase. 1901p21 expression, 1591

p53 expression, 1591

p53 expression, validation, 2007

urokinase plasminogen activator, 613

RNA content, biological significance.

419

systemic therapy response, PET and,

933

lymph node metastases, 1887

TGF-�3, secretion

stimulation by TNF-a, 827

treatment failure

Her2/neu overexpression, I 509

Carcinoma, cervicalCD3 � expression. peripheral blood

lymphocytes, I 825

mieronutnent plasma levels, I 81paclitaxel activity. 1285

telomerase activity, 2023

Carcinoma, colonadjuvant therapy

sulindac plus 5-FU and levamisole.

phase I trial, 37

cisplatin resistance

thioredoxin, 427fluoropyrimidine efficacy and

thymidylate synthase inhibition,

murine 26-B tumors, 1327

growth inhibition by anti-EGF-related

growth factor antisenseoligonucleotides. 601

therapy

cytotoxicity. potentiation by wild-type

p53. 1649

wild-type p53 dominance, 1639

xenografts

5’-AdThd modulation of IdUrd

metabolism, 981

Carcinoma, colorectalc-mvc overexpression. 1049

immunotherapy

active specific, Newcastle disease

virus-infected autologous tumor cell

vaccine, 2 I

metastases

dual antibody therapy with interferon,

1811

liver, c-src and c-yes activation, 1397

p53 point mutations, 1049

radiosensitization by adenovirus wild-

type p53. 1665

radiosensitization by 5-fluorocytosine,

53

Carcinoma, ductal breastapoptosis loss. I 887

Carcinoma, endometrialabnormal glycolipid expression,

quantitative assay. 749

and tamoxifen, 223

telomerase activity. 2023

tumor blood vessel markers

eosinophil peroxidase. 1867

Carcinoma, epithelialovarian

docetaxel, phase II study. 837

Carcinoma, fallopian tuberefractory

carboplatin combined with

cyclosporine A, phase II trial, 1693

Carcinoma, gastricBAGE, GAGE, and MAGE gene

expression, 1619

cisplatin resistance

thioredoxin. 427intestinal-type

angiogenesis. 1679

K-sam protein, immunohistoehemicaldetection. I 373

Carcinoma, germ celladvanced

platinum-DNA adduets. 1063

Carcinoma, gynecologicrefractory

intravenous earboplatin and

cyclosporine A, phase I trial. 1699

Carcinoma, head and neckglutathione S-transferase staining, 1859

Carcinoma, hepatocellularchemosensitization

cyclosporine A, post-liver transplant

patient plasma, 531

multidrug resistance. murine model. 695

Carcinoma, laryngealoccult neck metastases, 1801

Carcinoma, lunganti-erhB-2 oncotoxin activity. 75

endogenous mutant p53-specific CTLs,

877prognostic markers

K-ras mutations, 41 1

thrombomodulin, 763

retinoblastoma gene family expression.1239

second, genetic analysis, I 103

serum cytokine levels, 553

vascular endothelial growth factor

mRNA expression. 141 1Carcinoma, non-small cell lung

advancedpaclitaxel, phase II study. 941

bel-2 protein expression, 915

chromosome 3p loss of heterozygosity,

I 185

K-ras mutations, 1083

orthotopie humananti-erbB-2 effects, 1851

p53 protein expression

prognostic significance. I 55

retinoblastoma and, I 169

and survival time, 915

prognosis

biological parameters. model. I()67

retinobbastoma protein expression. I I 69

TIMPI expression and adverse

prognosis, 1369Carcinoma, ovarian

cell motility inhibition by paclitaxel(Taxol), 1725

cyclic AMP-binding proteins, 201

immunotherapyactive, gene modification of tumor

cells, 59

p21 expression and p.53 mutation. 1571

refractory

earboplatin combined with

eyelosporine A, phase II trial. 1693

refractory advanced

docetaxel, phase II study. 837

signal transduction defects, tumor-

associated lymphocytes. 161

tebomerase activity, 2023tumor blood vessel markers

eosinophil peroxidase, 1867

variant and wild-type estrogen receptors,

2029

Carcinoma, pancreatichyaluronan receptors expression, 1607

Carcinoma, prostaticandrogen and glucocorticoid receptors.

889apoptosis

phenylbutyrate induction. 379

AR gene mutations, 277bel-2 protein expression. 389

chromosomal aneusomies, prognosticvalue, 137

clustered p53 immunostaining, 399hormone-refractory

‘�#{176}Y-CYl-356 treatment, 1289metastatie variants, orthotopie

implantation in nude mice, 1627

progression

trisomy 7 marker. 1553

prostate-specific membrane antigen

folate hydrolase, 1445

TGF-�3 I receptor expression. 1255

TGF�3R-Il levels, 635

2058 Subject Index

xenografts

LuCaP 23, characterization, 1039Carcinoma, renal

local tumor irradiation combined withIL-2 therapy, murine, 1543

Carcinoma, renal celllL-l3 antitumor effects, 1743MHC class I, LMP, and TAP genes,

1427

13-cis-retinoic acid antiproliferativeeffects, 1077

retinoic acid receptor �3 expression,1077

Carcinoma, small cell lunggemeitabine pharmacokinetics and

metabolism, 359second lung cancer, genetic analysis,

1 103

Carcinoma, squamous cellcervical

paclitaxel activity, 1285

esophageal

cyclin A overexpression, 1781

cyclin Dl gene amplification, TNM-

Gene, 1155EGFR gene amplification, 909

head and neckantitumor effects of cisplatincombined with ALRT1O57, humanxenografts, 5 1 1apoptosis by ATRA and 4HPR, 855

cytotoxie therapy, tumor cellproliferation, 1453growth stimulation by interleukin 4,127

human papilloma virus and p53, 755

microsatellite alterations at llp boci,

903radiotherapy, bcl-2 protein andprognostic significance after, 261

recurring, p53 mutations, 1577

topical gene therapy, organotypic

model, 1659laryngeal

cyclin DI gene amplification, 175lung

‘31l-labeled EGF radiolocalization, 13

thrombomodulin, prognostic value,

763

oralantitumor effects of cisplatin

combined with ALRI1OS7, human

xenografts, S 1 1Carcinoma, thyroid

CD44 mRNA isoforms, 1251c-myc overexpression, 119Mr 67,000 expression, 1777

Carcinoma, transitional cellbladder

multifocal, molecular screening with

p53 mutations, 1795p53 mutations and, 1055

recurrencedetection, clonality and, 1795

Carcinoma in situ, breastpreinvasive vascularity, 1873

Carmustinecombined with streptozocin, refractory

melanoma, I 129�1-Carotene

plasma levels, cervical intraepithelial

neoplasia and cancer, 181

Carzelesinphase I clinical and pharmacokinetie

study. 1717Cathepsin B

malignant lung tissue, 561

prognostic significance, breast cancer,

613Cathepsin D

malignant lung tissue, 561

prognostic significance, breast cancer,613

Cathepsin Lmalignant lung tissue, 561

prognostic significance, breast cancer,

613CD3

peripheral blood lymphocyte expression,cervical cancer. I 825

CD8I cells

GM-CSF release, melanoma I-cellepitope detection and, 87

CD2Oanti-CD2O mAb

‘�#{176}Y-labe1ed,recurrent B-celllymphoma therapy, 457

CD44

expression, pancreatic carcinoma. 1607mRNA isoforms, thyroid and breast

carcinoma, I 251variant isoforms, malignant melanoma,

447

Cell cycleG2 checkpoint

inhibitor UCN-0b, cisplatin

cytotoxicity and, 791

Cell death: see also Apoptosis

ceramide and, I

cisplatin-induced

modulation by growth factors, ovariancancer, 1307

HSV-IK DNA and gancielovir, 47p53 protein. 435

programmedpaclitaxel-induced, MDA-MG-468

cells, 847

polyamine analogue-induced, lungtumor cells, 441

all-trans retinoic acid and antireceptor

antibodies and, myeloma, 253

Cell growthall-trans retinoic acid and antireceptor

antibodies and, myeloma, 253

Cell proliferationcytotoxic therapy, head and neck

tumors, 1453prognostic significance. breast

carcinoma, 147Cells

-mediated immunity

lymphocytes, 785

p53 protein, 435

Ceramideand apoptosis induction, I

c-erb-B2

anti-erbB-2 oncotoxin, orthotopic human

lung cancer, 1851overexpression

apoptosis modulation. MCF-7 cells,

1215

Cervical carcinoma

mieronutrient plasma levels, 181

paclitaxel activity. 1285

peripheral blood lymphocyte CD3 �

expression. 1825

telomerase activity, 2023

Cervical intraepithelial neoplasiamieronutrient plasma bevels, 181

CGP 41251growth inhibition, glioblastoma, 1017,

I638

Chemosensitivity

apoptotie tumor cell death and, 623

-directed regional chemotherapy.

prospective decision-aiding trial. 1469

enhancement by gene therapy. 1089

Chemosensitization

cyclosporine A, post-liver transplant

patient plasma, 531

Chemosensitizers

P-glyeoprotein inhibition. serum

bioassay, 403

Chemotherapy: see also specific agents

bifunctional anthracycline and

nitrosourea, bladder cancer, 1315

combined with cyclosporine, intraocular

retinoblastoma, 1499

differentiation-inducing

telomerase inhibition, 799

high-dose

breast cancer treatment failure, Her2/

izeu overexpression, 1509

-induced cell death

modulation by growth factors, ovarian

cancer, 1307

regionalchemosensitivity-directed, prospective

decision-aiding trial, 1469

resistance

cytokeratin expression and, 97

standard-dose adjuvant

breast cancer treatment failure, Her2/

imeu overexpression, I 509

chl8-IL2effeetor cell activation. 1951

Childrenacute lymphocytic leukemia

red blood cell methotrexatepharmacology. 331

Chloroacetaldehydemultidrug resistance protein

modification, 1321

Choriocarcinomatelomerase activity, 2023

Chromosome 3ploss of heterozygosity, non-small cell

lung cancer, 1 185

Chromosome 4aneusomy, breast carcinoma, 883

Chromosome 6aneusomy. breast carcinoma. 883

long arm

loss of heterozygosity. breast cancer.

1601

short arm

rearrangement. melanoma, 641

Chromosome 7aneusomy, breast carcinoma, 883

Chromosome 8

Clinical Cancer Research 2059

aneusomy

breast carcinoma. 883

prostate carcinoma, I 37

Chromosomes 9-12

aneusomy. breast carcinoma, 883

Chromosome 1 ip

microsatellite alterations. head and neck

squamous carcinoma, 903

Chromosome l3ql4

deletions. B-cell chronic lymphocytic

leukemia, 1673

Chromosome 17

aneusomy, breast carcinoma, 883

Chromosome 17p

loss of heterozygosity, medulboblastoma,

I 559

Chromosome 18

aneusomy. breast carcinoma, 883

Chromosomes-specific aneusomy

breast carcinoma. 883

prostate carcinoma. I 37

Chromosome X

aneusomy. breast carcinoma. 883

Chromosome Y

aneusomies, prostate carcinoma. 137

Chronic obstructive pulmonary diseaseserum anti-p53 antibodies, predating

cancer, 1767

Cisplatinaccumulation and passive permeability.

modulation by genistein. 991

cell death

modulation by growth factors. ovarian

cancer, 1307

combined with ALRT 1057

antitumor effects, human oral

squamous carcinoma xenografts, 5 I I

cytotoxicity

9-aminocamptothecin potentiation,

687

UCN-0l enhancement, 791

gemeitabine interactions, 521

platinum-DNA adducts, ICP-MS

quantitation. 1829

resistance

thioredoxin. 427

Clonality

bilateral breast cancer, 743

and transitional cell carcinoma

recurrence detection, I 795

c-myc

overexpression

coloreetal carcinoma, 1049

thyroid carcinogenesis, 1 19

c-neuoverexpression

apoptosis modulation, MCF-7 cells,

1215

Colonmalignant

alkyltransferase. quantitative

immunohistochemistry. 577

Colon adenocarcinomairinotecan combined with 5-fluorouracil

or etoposide. xenograft models, 107

Colon carcinomaadjuvant therapy

sulindac plus 5-FU and levamisole.

37

5’-Adlhd modulation of IdUrd

metabolism, xenografts. 981

cisplatin resistance

thioredoxin, 427

fluoropyrimidine efficacy and

thymidylate synthase inhibition,

murine 26-B tumors, 1327

growth inhibition by anti-EGF-related

growth factor antisense

oligonucleotides. 601

therapy

cytotoxicity. potentiation by wild-type

p53. 1649

wild-type p53 dominance. 1639

Colon rhabdomyosarcoma

irinotecan combined with 5-fluorouracil

or etoposide, xenograft models. 107

Colon tumorsfluoropyrimidine efficacy and

thymidylate synthase inhibition,

murine 26-B tumors. 1327

Colorectal carcinomac-mvc overexpression. I 049

GlutI overexpression. I 151immunotherapy

active specific. Newcastle disease

virus-infected autologous tumor cell

vaccine, 21

metastases

dual antibody therapy with interferon,

1811

liver. c-src and c-yes activation, 1397

p53 point mutations, 1049radiosensitization by adenovirus wild-

typep53. 1665

radiosensitization by 5-fluorocytosine,

53Colorectal tumors

apoptosis. 1999

Complementary DNAalkyltransferase

retroviral transfer, human

hematopoietic progenitors, I 353

Costimulatory molecules

expression, lymphoma liver metastasis,

811

CPT-ll: see Irinotecanc-src

activation, colorectal carcinoma liver

metastases. I 397

CTL: see Cytotoxic T lymphocytesCyanine

tellurium-containing

anticarcinoma activity. mitoehondria.

I 335

Cyclic adenosine 3’,S’-monophosphate-

binding proteinsovarian cancer, 201

Cyclin Aoverexpression. esophageal squamous

cell carcinoma, 1781

Cyclin Dlgene amplification

laryngeal squamous cell carcinoma,

175

prognostic significance, breast cancer,

I 177

TNM-Gene, squamous cell carcinoma

of esophagus. 1155

mRNA levels, breast cancer, 923

Cyclophosphamide

high-dose

cyclophosphamide and

4-hydroxycyclophosphamide/adophosphamide

kinetics, 1481

kinetics, high-dose cyclophosphamide

chemotherapy, 1481

Cyclosporincombined with chemotherapy.

intraocular retinoblastoma, 1499

Cyclosporin Achemosensitization, post-liver transplant

patient plasma. 531

combined with carboplatin

refractory gynecologic cancer, phase I

trial, 1699

refractory ovarian and fallopian tube

cancer, phase II trial, 1693

prevention of MDR I upregulation. 713

c-yesactivation, colorectal carcinoma liver

metastases, I 397

Cytarabinecombined with methotrexate

red blood cell pharmacology. acute

lymphocytie leukemia in children,

311

continuous infusion

fludarabine interactions, 653

Cytokeratin

expression

and drug resistance, 97

Cytokinesserum levels, lung cancer, 553

Cytolysistumor cell, I-cell-mediated, l()0l

Cytosine arabinosidecombined with B43-PAP. B-cell

precursor leukemia. 1533

Cytosine deaminasegene

5-fluorocytosine radiosensitization

and, colorectal carcinoma, 53

Cytotoxicitycisplatin

9-aminocamptothecin potentiation,

687

UCN-0l enhancement, 791cisplatin combined with ALRTIO57.

human oral squamous carcinoma

xenografts. 51 1

potentiation by wild-type p53. colon

cancer. 1649

TNF-Bl(Fv) fusion protein activity. Le�’antigen-expressing cells, 1523

Cytotoxic therapytumor cell proliferation, head and neck

tumors. 1453

Cytotoxic T lymphocytesmutant p53-specific, lung cancer cells,

877

D

DacarbazineDNA damage

peripheral white blood cells,

malignant melanoma. 303

DCC

loss of expression, disseminated

neurobbastoma, I 097

DDATHF: see Lometrexol

2060 Subject Index

cis-Diamminedichloroplatinum(II): see

Cisplatin5,10-Dideazatetrahydrofolic acid: see

LometrexolDietary folate

and folate receptor expression.neoplastic murine tissue, I I 35

Dihydrofolate reductaseinhibitors

MDAM, antitumor effects, 707Dihydropyrimidine dehydrogenase

deficiency

5-fluorouracil neurotoxicity, 477

peripheral blood mononuclear cells and

liver, 507

Dihydropyrimidinuriaasymptomatic adult, 1937

Dipyridamolecombined with PALA and fluorouracil,

advanced cancer, 1 107

Dissemination

DCC boss of expression. neuroblastoma,

1097Disulfide-stabilized Fv immunotoxins,

245

DNA

breast carcinoma content, flow

cytometric analysis, 419

HSV-IKcombined with ganciclovir.

melanoma, 47DNA adducts

methyl

peripheral white blood cells,

malignant melanoma treated with

dacarbazine and hydroxyurea, 303

platinum

advanced germ cell cancer, 1063

ICP-MS quantitation, peripheral bloodleukocytes. 1829

DNA damagedacarbazine-induced

peripheral white blood cells,

malignant melanoma, 303

p53 response

tamoxifen and, 1439

DNA repair

mismatch

genes. sporadic endometrial tumors,

1907nueleotide excision

fludarabine-mediated inhibition, and

apoptosis, 1731

peripheral white blood cells, malignant

melanoma treated with dacarbazineand hydroxyurea, 303

Docetaxel

refractory advanced ovarian carcinoma,phase II study, 837

DoxorubicinMRP-mediated drug resistance

glutathione depletion and. 1961

pharmacodynamics, bladder tumors,

I 275resistance

cytokeratin expression and. 97PAK-104P reversal, 369

Drug interactions

cisplatin and gemeitabine. 521

fludarabine and continuous infusion

cytarabine. 653

Drug resistance: see also Multidrugresistance; specific drugs

cytokeratin expression and, 97

Drugs: see also specific drugs

drug-induced apoptosis

modulation by PKC signal

transduction pathway. 1915

exposure after intraperitoneal

administration

vasopressin and, 3 1 1

intraperitoneal

pharmacokinetics, vasopressin and,

311

Dysplasia: see also Myelodysplasticsyndrome

cervical

micronutrient plasma levels, 181

E

Eastern Cooperative Group TrialIFN--y, metastatie melanoma, 29

Edatrexatehigh-dose

combined with oral leucovorin, phase

I trial, 1819

EfTector cells

activation by anti-GD2-1L2 fusion

protein, 1951

e23(Fv)PE38KDELlung cancer activity, 75

orthotopic human lung cancer, 1851

EGF: see Epidermal growth factorEndometrial carcinoma

abnormal glycolipid expression,

quantitative assay, 749

and tamoxifen, 223telomerase activity, 2023

tumor blood vessel markers

eosinophil peroxidase. 1867

Endometrial tumorssporadic

DNA mismatch repair genes, 1907

EndometriumMDRI expression. 1981

Endothelial growth factorvascular

intestinal-type gastric cancer, I 679

mRNA expression, lung cancer, 141 1

serum levels, 821

Enzyme-linked immunosorbent assayp53 protein

prognostic significance. non-small cell

lung cancer, 155

Eosinophil peroxidase

tumor blood vessels, ovarian and

endometrial cancers, I 867

Epidermal growth factoranti-EGF-related growth factor antisense

oligonucleotides

growth inhibition, colon carcinoma.

601

‘31l-labeled

squamous lung carcinoma

radiolocalization, I 3

receptor

expression, metaplastic bronchial

epithelium, 1787

gene amplification. esophagealsquamous cell carcinoma. 909

Epithelial cells

mammary

lymphokine-activated killing

sensitivity. 207

ovarian

malignant. p2l expression and p53

mutation, 1571

Epithelial ovarian carcinomarefractory to platinum

docetaxel. phase II study. 837

Epithelium

androgen and glucocorticoid receptors.

prostatic hyperplasia and carcinoma,

889

metaplastic bronchial

EGFr expression, 1787Epitopes

I-cell

melanoma, detection. 87

erbB-2anti-erbB-2 oncotoxin

lung cancer. 75

orthotopic human lung cancer, I 851

erbB-3

receptors

tumor cells expressing, T cell-

mediated cytolysis. l(X)l

erbB-4receptors

tumor cells expressing. I cell-

mediated cytolysis, l0()l

Erythrocytesglucose transporter

overexpression, colorectal

carcinogenesis. I 151

methotrexate pharmacology. acute

lymphocytic leukeniia in children,

331

Erythropoiesisstimulation by stem cell factor,

myelodysplastic syndrome, I 031

Esophageal squamous cell carcinoma

cyclin A overexpression. 1781

cyclin Dl gene amplification, TNM-

Gene, 1155EGFR gene amplification. 909

Estrogen

plasma

suppression by megestrol acetate,

postmenopausal breast cancer. I 5 15

receptors

FES-PET and, breast cancer, 933gene methylation. breast tumors, 805

mRNA levels, breast cancer, 923

status. angiogenesis determination

and, 1191

variant and wild-type, ovarian

carcinoma, 2029

3-Ethyl-3’-methyl-

thiatelluracarbocyanine iodide

anticarcinoma activity. mitochondria,

I335

7-Ethyl-l0-(4-i-piperidinoj-l-piperidino)-carbonyloxy-camptothecin: see

IrinotecanEtoposide

combined with irinotecan, colon

adenocarcinoma or

rhabdomyosarcoma xenograft models.

107

Clinical Cancer Research 2061

F

Fallopian tube cancerrefractory

carboplatin combined with

cyclosporin A. phase II trial. 1693

Fatty acids

aromatic

multidrug resistance vulnerability. 865

omega-3

suppressive effects. breast cancer.

1751

Ferecombinant human TNF receptor

chimera

combined with IL-2. phase I trial,

I 341

FDG: see 2-I’8F]Fluoro-2-deoxy-u-

glucoseFES: see l6a-[m8F]Fluoro-l7�3-estradiol

Fibronectinserum levels. immunotoxin therapy,

1705

Flavonoids

quercetin. phase I clinical trial, 659

Flow cytometryDNA/RNA content. breast carcinoma.

419

GG918 inhibition by Pgp. 7Flow resistance

gemcitabine. small cell lung cancer. 359

Fludarabinecytarabine interactions. 653

nucleotide excision repair inhibition

and apoptosis. quiescent lymphocytes.

1731

Fluorescence in situ hybridization

chromosomal aneusomies, prostate

carcinoma, 137

chromosome 13ql4 deletions. B-cell

chronic lymphocytic leukemia, 1673

dual-color

trisomy 7. prostate cancer. 1553

5-Fluorocytosine

radiosensitization. colorectal carcinoma.

532-I ‘8FlFluoro-2-deoxy-D-glucose

positron emission tomography. breast

cancer, 933

l6Q�lmKFlF1uoro�l7��estradio1

positron emission tomography. breast

cancer. 933

Fluoropyrimidine

therapeutic efficacy

and thymidylate synthase inhibition.

colon 26-B tumors. 1327

Fluorouracilcombined with iododeoxyuridine and

leucovorin. phase I trial. 1475

combined with PALA and dipyridamole.

advanced cancer, I 107

5-Fluorouracil

catabolism

hepatic, ‘�F MRS quantitation. 339

combined with irinotecan, colon

adenocarcinoma or

rhabdomyosarcoma xenograft models.

107

combined with levamisole and sulindac,

colon carcinoma, 37

cytotoxicity

potentiation by wild-type p53, colon

cancer. I 649

neurotoxicity, dihydropyrimidine

dehydrogenase deficiency. 477

prodrug tegafur

combined with uracil. phase I and

pharmacokinetic study, 1461

Folate

analogue thymidylate synthase

inhibitors, 227

dietary

and folate receptor expression.

neoplastic murine tissue. I 135

receptors

dietary folate and. neoplastic murine

tissue, I 135

Folate hydrolaseprostate-specific membrane antigen,

prostatic carcinoma cells. 1445

Folinic acid rescue

combined with lometrexol, phase I

study. 1123

5-FU: see 5-Fluorouracil

Fusion proteinanti-GD2-1L2

effector cell activation, 1951

GM-CSF/IL-3effects on human tumor colony-

forming units. 1713

TNF-Bl(Fv). 1523

Fv immunotoxinsdisulfide-stabibized, 245

e23(Fv)PE38KDEL

lung cancer activity. 75

orthotopic human lung cancer, 185 I

recombinant

antibody engineering, 245

TNF-B I (Fv)

cytotoxic antitumor activity. Le�

antigen-expressing cells. 1523

GAGE

G

expression. gastric carcinoma. 1619

Gallium nitrateresistance

transferrmn and Ga-PIH and, lymphoid

leukemic cells, 1009

Gallium-pyridoxal isonicotinoylhydrazone

and resistance to gallium nitrate.

lymphoid leukemic cells, 1009

Ganciclovir

combined with HSV-TK gene transfer.

melanoma. 47

Ganglioside

GD2

anti-GD2-IL2 fusion protein. effector

cell activation. 1951

GD3BEC2 anti-idiotypic antibody mimic,melanoma. 679

Gastric carcinomaBAGE, GAGE. and MAGE gene

expression, 1619

cisplatin resistance

thioredoxin, 427

intestinal-type

angiogenesis, 1679

K-sam protein, immunohistochemical

detection. 1373

Gemcitabineinfusion pharmacokinetics and

metabolism, small cell lung cancer.

359

interactions with cisplatin. 521

Genes: see also Oncogenes; Proto-

oncogenes

androgen receptor (AR)

mutations. prostate cancer, 277

BAGE

expression, gastric carcinoma, 1619

cyclin Dl (CCNDI)

amplification, breast cancer, I 177

amplification, laryngeal squamous cell

carcinoma. I 75

amplification. TNM-Gene. I 155

expression. breast cancer. 923

cytosine deaminase

5-fluorocytosine radiosensitization

and, colorectal carcinoma, 53

DCC

loss of expression. disseminated

neuroblastoma, 1097

DNA mismatch repair. sporadic

endometrial tumors. I 907

epidermal growth factor receptor

( EGFR)

amplification. esophageal squamous

cell carcinoma, 909

estrogen receptor (ER)

expression, breast cancer, 923

methylation, breast tumors, 805

GAGEexpression. gastric carcinoma, I 6 I 9

K-ras

mutations. lung carcinoma. 41 1

mutations. non-small cell lung

carcinoma. 1083

MAGE

expression. gastric carcinoma. 1619

MDR

transfer into peripheral blood

progenitor cells. 873

MDRJ

bisantrene resistance. 973

expression, breast carcinoma, I 231

expression. endometrium, I 981

upregulation prevention by

cyclosporin A and PSC 833. 713

MRP

expression. breast carcinoma, 123 1�/6iNK4a

expression. breast cancer. 1993

p1 #{231}�ARF

expression. breast cancer. I 993

p53endogenous mutant CTL target. lung

cancer cells. 877

human papilloma virus and. head and

neck cancer. 755

mutations, bladder cancer, 1055

mutations. p21 expression and. 1571

mutations, recurring head and neck

cancer, 1577

point mutations, colorectal carcinoma,

I ()49

p’07expression. lung cancer, I 239

poly(ADP-ribose) polymerase ( PARP)

2062 Subject Index

expression and genomic instability,

breast cancer, 1 163

pRb/p105

expression, lung cancer, 1239

pRb/p130

expression, lung cancer, 1239

progesterone receptor (PR)

methylation, breast tumors, 805

retinoblastoma family

expression, lung cancer, 1239

retinoblastoma (RB)

expression, lung cancer, I 239

somatostatin receptor type 2

expression, neuroblastoma, 1757

TAP

MHC class I and, renal cellcarcinoma, 1427

TIMPI

expression and adverse prognosis,

non-small cell lung cancer. 1369

INM-Genecyclin Dl gene amplification,

squamous cell carcinoma of

esophagus, 1155

tumor antigen

expression, gastric carcinoma, 1619

wild-type p53

adenovirus, radiation sensitization,

1665Gene therapy

chemosensitivity enhancement, 1089

topical

head and neck squamous cell

carcinoma, organotypic model. I 659

Gene transferliposome-mediated

active immunotherapy, breast and

ovarian cancer, 59retroviral MDR1

bisantrene resistance, 973

retroviral MDR, peripheral blood

progenitor cells, 873

retroviral MGMT, human hematopoietic

progenitors, 1353

virus-free HSV-TK

combined with ganeiclovir,

melanoma, 47

Genisteinmodulation of cisplatin accumulation

and passive permeability, 991

Genomic instabilityleukemia, 1583PARP expression and, breast cancer,

1 163

Germ cell canceradvanced

platinum-DNA adducts, 1063

Germ cell tumorsmetastatie nonseminomatous

serum tumor marker half-life, 1565

GG918Pgp inhibition, flow cytometric assay, 7

Glioblastomagrowth inhibition by CGP 41251, 1017,

1638

Glioblastoma multiformerecurrence

low-grade, biological and molecular

analysis, I 87

Gliomamalignant

hypericin-enhanced radiosensitivity,

843

recurrent, high-dose I 3-cis-retinoic

acid treatment, 1931

recurrent, high-dose tamoxifen

treatment, 619

Glucocorticoid

receptors

prostatic hyperplasia and carcinoma,

889

Glucose

erythrocyte transporter

overexpression, coborectal

careinogenesis, I I S I

Glutathionedepletion

and multidrug resistance protein

function, 1961

Gbutathione S-transferaseimmunohistochemical staining, head and

neck cancer, 1859Gluti protein

overexpression. coloreetal

earcinogenesis, 1 151

Glycolipid

abnormal endometnab expression,

quantitative assay, 749

Glycoprotein 75cell surface target, melanoma, 1837

GM-CSF: see Granulocyte-macrophage

colony-stimulating factor

Granulocyte colony-stimulating factorcombined with topotecan, phase I trials,

1489

serum levels, lung cancer, 553

Granulocyte-macrophage colony-

stimulating factor

CD8� I-cell releasemelanoma I-cell epitope detection

and, 87

combined with IL-2, phase lB study,

319

GM-CSFIIL-3 fusion proteineffects on human tumor colony-

forming units, 1713

serum levels, lung cancer, 553

Growth factorEGF-related

anti-EGF-related growth factor

antisense oligonucleotides, colon

carcinoma, 601

epidermal

‘31I-labeled, squamous lung

carcinoma radiobocalization, I 3

receptor expression, metaplastic

bronchial epithelium, 1787

receptor gene amplification,

esophageal squamous cell carcinoma,

909insulin-like, I

regulation by ICI 182780, 2037

lipid

cisplatin-induced cell death

modulation, ovarian cancer, 1307

modulation

gene therapy strategy and

chemosensitivity enhancement, 1089

paracrine

interbeukin 6, breast carcinoma, 215

peptide

cisplatin-induced cell death

modulation, ovarian cancer, 1307

platelet-derived

l� receptors. breast carcinoma, 773transforming. 1�2

stimulation by INF-a. MCF-7 cells,

827

vascular endothelial

intestinal-type gastric cancer. 1679

mRNA expression, lung cancer, 141 1

serum levels, 821

Gynecologic cancer

refractory

intravenous carboplatin and

cyclosporin A, phase I trial, 1699

telomerase activity. 2023

H

Head and neck cancerglutathione S-transferase staining, 1859

Head and neck squamous cellcarcinoma

antitumor effects of cisplatin combined

with ALRTIO57, human xenografts.

511

apoptosis by ATRA and 4HPR, 855

cytotoxic therapy

tumor cell proliferation, 1453

early stage

radiotherapy, bcl-2 protein and

prognostic significance after. 261

growth stimulation by interleukin 4, 127

human papibboma virus and p53, 755

microsatellite alterations at llp loci, 903

recurring

p53 mutations, 1577

topical gene therapy, organotypic model,

1659

Head and neck tumorscytotoxic therapy

tumor cell proliferation, 1453

Heat shock protein 27prognostic significance, node-negative

breast cancer, 1 199

Hematological neoplasiareplication errors, 1583

Hematopoietic progenitor cells

autologous

breast cancer treatment failure, Her2/

nets overexpression, 1509

human

retroviral MGMT gene transfer, 1353

Hematotoxicitybisantrene-specific

resistance, retroviral MDR1 gene

transfer, 973

Hepatocellular carcinoma

chemosensitization

cycbosporin A, post-liver transplant

patient plasma. 531

multidrug resistance, murine model. 695

Hepatomamultidrug resistance, murine model, 695

HER2

overexpression

apoptosis modulation, MCF-7 cells,

1215

HER2/neuoncotoxin. orthotopic human lung

cancer, 1851

Clinical Cancer Research 2063

Fv

overexpression. breast cancer treatment

failure, 1509

Herpes simplex virus thymidine kinasegene transfer

combined with ganciclovir,

melanoma, 47

Heterozygosity, loss ofchromosome 3p. non-small cell lung

cancer, 1185

chromosome 6q, breast cancer, 1601

chromosome I7p. medulboblastoma,

1559

HLA: See Human leukocyte antigen

Hormonesrefractory prostate cancer

9�Y-CYT-356 treatment, 1289

4HPR: see N-(4-

Hydroxyphenyl)retinamideHSP: see Heat shock protein

HSV: see Herpes simplex virusHT-29 cells

thioredoxin, 427

Human leukocyte antigen

Al

melanoma T-cell epitopes. detection,

87

A2

melanoma loss, 641

Human papilloma virus

and p53, head and neck cancer, 755

Human tumor colony-forming assay

chemosensitivity

-directed regional chemotherapy,

prospective decision-aiding trial, 1469

Hyaluronanreceptor expression, pancreatic cancer

cells. 1607

Hybrid protein

pml/RAR-a

immune recognition. acute

promyelocytic leukemia, 593

4-Hydroxycyclophosphamide/adophosphamidekinetics, high-dose cyclophosphamide

chemotherapy, 1481

N-(4-Hydroxyphenyl)retinamideapoptosis induction, head and neck

squamous cell carcinoma cell lines,

855

7-Hydroxystaurosporinecisplatin-induced cytotoxicity and, 791

Hydroxyureacombined with dacarbazine

DNA damage, malignant melanoma,

303

Hypericin-enhanced radiosensitivity, malignant

glioma cells. 843

Hyperplasia

prostatic

androgen and glucocorticoid

receptors. 889

Hypoxanthine-guanine phosphoribosyl

transferasemutations

peripheral white blood cells,

malignant melanoma, 303

I

ICI 182780IGF-IR regulation. 2037

ICP-MS: see Inductively coupled plasmamass spectroscopy

IdUrd: see Iododeoxyuridine

IFN: see Interferon

IGF: see Insulin-like growth factor

IL: see Interleukin

Immune recognitionpml/RAR-a, acute promyelocytic

leukemia. 593

tumor escape. melanoma, 641

Immunity

cell-mediated, lymphocytes, 785

Immunization

BEC2 anti-idiotypic vaccine, melanoma,

679

Immunodeficiencysevere combined

B-cell precursor leukemia, B43-PAP

plus cytosine arabinoside treatment,

1533

multidrug resistance, murine

hepatoma model, 695

Immunoglobubin G

recombinant human TNF receptor

chimera

combined with lL-2, phase I trial,

1341

Immunohistochemistryglutathione S-transferase staining, head

and neck cancer, 1859

K-sam protein detection, stomach

cancer, 1373

MDRJ expression, endometrium, 1981

Mr 67,000 expression. thyroid cancer,

1777

p21 and p53 expression. breast

carcinoma, 1591

predictors of occult neck metastases,

laryngeal carcinoma. 1801

quantitative

alkyltransferase. malignant colon, 577

steroid receptors, prostatic hyperplasia

and carcinoma. 889

TGF�3R-II bevels, prostate cancer, 635

Immunomagnetic purging

peripheral blood progenitor cells, breast

cancer, 81

ImmunoreactivityMel-CAM, mesenchymal neoplasms.

569

Immunostaining

clustered p53. prostate carcinoma, 399

Immunotherapy

active

gene modification of tumor cells,

breast and ovarian cancer. 59active specific

Newcastle disease virus-infected

autologous tumor cell vaccine,

colorectal carcinoma, 21

melanoma

TCR-V�3 repertoire after, 767

metastatic melanoma

signaling activity in I cells before

and after, 1263

serum fibronectin levels, 1705

Immunotoxinse23(Fv)PE38KDEL

lung cancer activity. 75

orthotopic human lung cancer, 1851

disulfide-stabilized, 245

recombinant, antibody engineering,

245

ricin A chain-containing

treatment, serum tibronectin levels,

1705

TNF-B l(Fv)

cytotoxic antitumor activity, Le’�’

antigen-expressing cells, 1523

Inductively coupled plasma mass

spectroscopyquantitation of platinum-DNA adducts,

peripheral blood leukocytes, I 829

Insulin-like growth factor I

receptor regulation by ICI I 82780. 2037

Interferondual antibody therapy with, metastatic

coborectal cancer, 18 1 1

Interferon �

metastatic melanoma trial, 29

Interleukin 1

receptor antagonist induction after IL- 1

therapy. 501

Interleukin 2

anti-GD2-IL2 fusion protein

effector cell activation, 1951

combined with GM-CSF, phase lB

study, 319

combined with rhuTNFR:Fc, phase I

trial,1341

immunotherapy

combined with local radiation, murine

renal carcinoma, I 543

I-cell signaling activity. metastatic

melanoma, I 263

TCR-V�3 repertoire after, melanoma,767

inhaled natural, pulmonary malignancy,

I I 15

liposomes

aerosol delivery, canine studies, 721

low-dose

daily subcutaneous injections, toxicity

and immunological effects, 669

and natural killer cells, metastatic

cancer, 493

non-MHC-restricted lymphokine-

activated killing

sensitivity, MCF-IOA cells, 207

Interleukin 3

GM-CSF/IL-3 fusion proteineffects on human tumor colony-

forming units. 1713

subcutaneous recombinant human

refractory malignancy, phase I trial,

347

Interleukin 4growth stimulation. head and neck

squamous cell carcinoma. I 27

Interleukin 6

anti-IL-6 receptor antibodies

combined with retinoids, myeloma

and, 253

growth-stimulatory factor, melanoma.

1417

levels, lung cancer, 553

levels, metastatic malignant melanoma,

1405

paracrine growth factor. breast

carcinoma, 215

Interleukin 10

2064 Subject Index

K-ras growth factors

antiangiogenic effects, melanoma, 1969

production, melanoma, 1383

Interleukin 13antitumor effects. renal cell carcinoma,

1743

Intestinal-type gastric carcinomaangiogenesis, 1679

Intraepithelial neoplasia, cervicalmicronutrient plasma levels, 181

Intrahepatic xenograftshepatocellular carcinoma

multidrug resistance, murine model,

695Intraocular retinoblastoma

chemotherapy combined with

cycbosporin, 1499

Intraperitoneal drugspharmacokinetics

vasopressin and, 3 1 1

Intratumor pharmacokineticsgemeitabine, small cell lung cancer, 359

Iododeoxyuridine

combined with leucovorin and

fluorouracil, phase I trial, 1475

metabolism modulation by 5’-AdThd,

colon cancer xenografts. 981

5-Iododeoxyuridineradiosensitization

leucovorin modulation, phase I study,

1299

Irinotecancombined with 5-fluorouracil or

etoposide, colon adenocarcinoma or

rhabdomyosarcoma xenograft models,

107

metabolites, bile and urine, 1943

K

KDR

intestinal-type gastric cancer, 1679

Keratin 18protein expression, breast cancer, 1879

Ki-67

prognostic value, axillary node-negative

breast cancer, 585

Kidney carcinomalocal tumor irradiation combined with

IL-2 therapy, murine, 1543

Kidney failurehigh-dose melphalan autotransplants,

947

Kinase

herpes simplex virus thymidine

gene transfer, combined with

ganciclovir, 47

protein, A

subunits, lymphokine-activated killing

sensitivity and, 207

protein, C

inhibitor COP 41251, growth

inhibition, 1017, 1638

signal transduction pathway, drug-

induced apoptosis modulation, 1915

protein tyrosine

pp6O’src, activation, 1397pp62�ves, activation, I 397

tyrosine

inhibition by quereetin, phase I

clinical trial, 659

mutations

lung carcinoma, 41 1

non-small cell lung carcinoma, 1083

K-sam protein

immunohistoehemicab detection,

stomach cancer, 1373

L

LamininMr 67,000 receptor

expression, thyroid cancer, I 777

Laryngeal carcinomaoccult neck metastases, 1801

squamous cell

cvclin Dl gene amplification, 175

telomerase activity, 1895

Leptomeningeal neoplasmsintrathecal ‘311-labeled 8 1C6 mAb

therapy, phase I trial, 963

Leucovorincombined with fluorouracil and

iododeoxyuridine, phase I trial, 1475

IdUrd radiosensitizaiton modulation,phase I study, 1299

oral

combined with high-dose edatrexate,

phase I trial, 1819

Leukemiagenomic instability, 1583

lymphoid

gallium nitrate resistance, transferrin

and Ga-PIH and, 1009

Leukemia, acute

refractory

topotecan, phase I study. 1921

Leukemia, acute lymphoblastictreatment

aminopterin, 69

Leukemia, acute lymphocytic

children

red blood cell methotrexate

pharmacology, 331

Leukemia, acute myelogenoustebomerase activity, 799

Leukemia, acute promyelocyticimmune recognition of pm1IRAR-ct, 593

Leukemia, B-cell precursorB43-PAP plus cytosine arabinoside

treatment, SCID mice, 1533Leukemia, chronic lymphocytic

B-cell

chromosome l3ql4 deletions, 1673

Leukemia, 1-celladult

-derived factor, cisplatin resistance,

427

Leukocytes

peripheral blood

platinum-DNA adducts, ICP-MS

quantitation, 1829

Levamisolecombined with 5-FU and sulindac, colon

carcinoma, 37

Le’ cellsantigen-expressing

INF-B1(Fv) fusion protein cytotoxic

antitumor activity, 1523

Lipids

cisplatin-induced cell death

modulation, ovarian cancer, I 307

Liposomes

interleukin 2

aerosol delivery, canine studies, 721

Liverdihydropyrimidine dehydrogenase

activity, 507

5-fluorouracil catabolism, ‘9F MRS

quantitation, 339

metastasis

adhesion and costimulatory molecule

expression, lymphoma, 81 1

c-src and c-yes, colorectal carcinoma,

1397

Liver carcinoma

cycbosporin A chemoenhancement, post-

liver transplant patient plasma, 531

Liver transplantcycbosporin A chemosensitization, post-

liver transplant patient plasma, 531

Liver tumorsregional chemotherapy

chemosensitivity-directed, prospective

decision-aiding trial, 1469

Lometrexolcombined with folinic acid rescue, phase

I study, 1123Loss of heterozygosity

chromosome 3p, non-small cell lung

cancer, 1185

chromosome 6q, breast cancer, 1601

chromosome l7p, medulloblastoma,

1559

Lovastatin

phase I study, 483

Low molecular weight proteinMHC class I and, renal cell carcinoma,

1427

LuCaP 23characterization, 1039

Lungchronic obstructive pulmonary disease

serum anti-p53 antibodies, predating

cancer, 1767

malignancy

cathepsins, 561

inhaled nIL-2, phase I trial, 1 1 15

metastasis

local tumor irradiation combined with

IL-2 therapy and, murine renal

carcinoma, 1543

Lung carcinomaanti-erbB-2 oncotoxin activity. 75

endogenous mutant p53-specific CILs,

877

non-small cell

advanced, paclitaxel. 941

bcl-2 protein expression. 915

chromosome 3p loss of

heterozygosity, I I 85

K-ras mutations, I 083

orthotopic human, anti-erbB-2 effects.

I851

p53 protein expression, 155, 915,

I 169

prognosis, biological parameters.

1067

retinoblastoma protein expression,

1 169

Clinical Cancer Research 2065

TIMPI expression and adverse

prognosis. 1369

prognostic markers

K-ras mutations, 41 1

thrombomodulin, 763

retinoblastoma gene family expression,

I 239

second, genetic analysis, I 103

serum cytokine levels. 553

small cell

gemeitabine pharmacokinetics and

metabolism. 359

squamous

I 31 I-labeled EGF radiolocalization, 13

vascular endothelial growth factor

mRNA expression. 141 1

Lung tumorscathepsins. 561

malignant

inhaled nIL-2, phase I trial, I 1 15

polyamine analogue-induced cell death,

441

Lycopene

plasma levels, cervical intraepithelial

neoplasia and cancer, 181

Lymphatic drug exposure

after intraperitoneal administration

vasopressin and, 3 1 1

Lymph nodesmetastases

Glut I overexpression and, colorectabcarcinogenesis. 1 151

I, breast cancer, 1887node-negative breast cancer

hsp27. 1199

Ki-67 vs S-phase fraction, 585

p53 expression, prognostic value,

2007

node-positive breast cancer

adjuvant tamoxifen. predictors of

outcome, 1191

treatment failure, Her2/neu

overexpression. I 509

Lymphocytes: see also B cells; I cellsactivation by anti-GD2-IL2 fusion

protein. 1951

peripheral blood

CD3 � expression. cervical cancer,1825

pml/RAR-a immune recognition. acute

promyelocytie leukemia, 593

quiescent

apoptosis, fiudarabine and, I 731

tumor-associated

signal transduction defects, ovarian

carcinoma. 161tumor cell killing. 785

Lymphoid leukemiagallium nitrate resistance, transferrmn and

Ga-PIH and, 1009

Lymphokine-activated killingsensitivity

modulation by oncogenes and protein

kinase A subunits, MCF-IOA cells,

207

Lymphomaliver metastasis

adhesion and costimulatory molecule

expression, 8 1 1

Lymphoma, B-cellrecurrent

9#{176}Y-labeled anti-CD2O mAb therapy.

457

Lysistumor cell

I-cell-mediated, I 001

M

Macrophage colony-stimulating factorrecombinant

continuous-infusion, metastatic

melanoma, 295

serum levels, lung cancer, 553

MAGEexpression, gastric carcinoma, 1619

Magnetic resonance spectroscopythree-dimensional localized ‘9F

hepatic 5-fluorouracil catabolism

quantitation. 339

Major histocompatibility complexclass I

and LMP and TAP genes. renal cell

carcinoma, 1427

Malignancy

colon

alkyltransferase. quantitative

immunohistoehemistry. 577

glioma

hypericin-enhanced radiosensitivity.

843

recurrent, high-dose 13-cis-retinoic

acid treatment, 1931

recurrent, high-dose tamoxifen

treatment, 619

lung tissue

cathepsins. 561

melanoma

CD44 variant isoforms, 447dacarbazine-induced DNA damage.

peripheral white blood cells. 303

metastatie melanoma

IL-6 levels, 1405ovarian epithelial cells

p2 1 expression and p53 mutation.

I 571

pulmonary

inhaled nlL-2, phase I trial. I 1 15

refractory

subcutaneous IL-3, phase I trial, 347

Mammary epithelial cells

lymphokine-activated killing sensitivity

modulation by oncogenes and protein

kinase A subunits, 207

Mass spectroscopyinductively coupled plasma

quantitation of platinum-DNA

adduets. peripheral blood leukocytes.

I829

Matrix metalloproteinasesinhibitor batimastat

growth inhibition. solid breast tumors.

1207

MCF-7 cellsapoptosis modulation by HER2

overexpression, 1215

TGF-�3� secretion

stimulation by INF-a, 827

MCF-1OA cellslymphokine-activated killing sensitivity

modulation by oncogenes and protein

kinase A subunits. 207

M-CSF: see Macrophage colony-stimulating factor

MDAM: see ‘y-Methylene-lO-deazaaminopterin

MDA-MG-468 cellspaclitaxel-induced death. 847

MDR: see Multidrug resistanceMedulloblastoma

chromosome 1‘lp loss of heterozygosity.

1559

Megestrol acetateplasma estrogen suppression.

postmenopausal breast cancer, I 515

Melanomaadvanced-stage

IL-6 growth-stimulatory factor, 1417chromosome 6 rearrangement, 641

HLA-A2 loss, 641

immunization

BEC2 anti-idiotypic vaccine, 679immunotherapy

ICR-V�3 repertoire after, 767

interleukin 10 antiangiogenic effects.

1969interleukin 10 production. 1383

malignant

CD44 variant isoforms, 447dacarbazine-induced DNA damage,

peripheral white blood cells. 303

metastatie

continuous-infusion recombinant M-

CSF, phase I study. 295IFN--y trial, 29

signaling deficiency, T cells, 1263

metastatic malignant

IL-6 levels. 1405refractory

carmustine and streptozocin, I I 29

T-eell epitopes, detection. 87treatment

HSV-IK DNA and ganciclovir. 47

melanosomal protein cell surface

target. 1837

Melanosomal proteincell surface target, 1837

Mel-CAMimmunoreactivity, mesenchymal

neoplasms, 569

Melphalanhigh-dose, multiple myeloma. 947

resistance

cytokeratin expression and, 97

Mesenchymal neoplasms

Mel-CAM immunoreactivity. 569Messenger RNA

CD44 isoforms. thyroid and breastcarcinoma. I 251

cyclin Dl and estrogen receptor

levels, breast cancer, 923

MDRIexpression, endometrium, I 981

vascular endothelial growth factor

expression. lung cancer. 141 1

Metabolismgemcitabine, small cell lung cancer, 359

irinotecan, 1943

Metaplasiabronchial epithelium

EGFr expression, 1787Metastasis

breast cancer

2066 Subject Index

omega-3 fatty acid suppressive

effects, 1751

p53 accumulation and, 2007

coboreetal cancer

dual antibody therapy with interferon,

1811

interbeukin 2 effects on natural killer

cells, 493

liver

c-src and c-yes, coloreetal carcinoma,

1397

lymph node

Glutl overexpression and, colorectalcareinogenesis, 1 151

I� breast cancer, 1887

lymphoma

adhesion and costimulatory molecule

expression, liver, 8 1 1malignant melanoma

IL-6 levels, 1405melanoma

continuous-infusion recombinant M-

CSF, phase I study, 295IFN--y trial, 29

signaling deficiency, I cells, 1263

suppression by IL-b, 1969

neck

occult, laryngeal carcinoma, 1801nonseminomatous germ cell tumors

serum tumor marker half-life, 1565occult neck

laryngeal carcinoma, I 801

prostatie carcinoma

variants, orthotopic implantation in

nude mice, 1627pulmonary

local tumor irradiation combined with

IL-2 therapy and, murine renal

carcinoma, I 543

Methotrexate

pharmacology

red blood cell, acute lymphocytic

leukemia in children, 331

MethylationER and PR genes, breast tumors, 805

Methylatorsresistance

MGMT and, brain tumor cell lines,735

Methyl DNA adductsperipheral white blood cells, malignant

melanoma treated with dacarbazineand hydroxyurea, 303

�y-Methylene-10-deazaaminopterinantitumor effects, preclinicab evaluation,

707

06-Methylguanine-DNAmethyltransferase

and brain tumor cell line methylator

resistance, 735

retrovirab gene transfer, human

hematopoietic progenitors. 1353

Mevabonateinhibitor lovastatin, phase I study, 483

MGMT: see 06-Methybguanine-DNAmethyltransferase

MIB-1and occult neck metastases, laryngeal

carcinoma, 1801

tumor cell proliferation rate, breast

carcinoma, 147

Micronutrientsplasma levels, cervical intraepithelial

neoplasia and cancer, 181

Microsatellite alterations

leukemia and myelodysplastic

syndrome, 1583

llp loci, head and neck squamous

carcinoma, 903

Microsatellite instability

sporadic endometrial tumors

DNA mismatch repair genes. 1907

Microvessel countprognostic model, non-small cell lung

carcinoma, 1067

Mitochondria

le anticarcinoma activity, 1335Mitomycin C

resistance

cytokeratin expression and, 97

Mitoxantroneresistance

cytokeratin expression and, 97

Molecular screeningp53 mutations, mubtifocab transitional

cell carcinoma of bladder, 1795

Monoclonal antibodyanti-CD2O

�#{176}Y-labeled, recurrent B-cell

lymphoma therapy. 457

antitenasein 81C6

intrathecal ‘31I-labeled, phase I trial

therapy, 963

BIINF-Bl(Fv) fusion protein, cytotoxic

antitumor activity. 1523

BEC2 anti-idiotypicimmunization, melanoma, 679

5C3IrkA protein detection,

neuroblastoma, 1361

MIB- 1and occult neck metastases, laryngeal

carcinoma, 1801

tumor cell proliferation rate, breast

carcinoma, 147

�#{176}Y-CYI-356hormone-refractory prostate cancer

treatment, 1289

Mononuclear cellsperipheral blood

dihydropyrimidine dehydrogenase

activity, 507

M�-[4-(Morpholinosulfonyl)benzyl-N�-

methyl-2,6-diaminobenz-[c,dJ-indole

glucuronate: see AG331Mr 67,000

expression, thyroid cancer, 1777mRNA: see Messenger RNAMRP: see Multidrug resistance proteinMRS: see Magnetic resonance

spectroscopy

MUC18: see Mel-CAMMultidrug resistance

inhibitor GG9I 8

Pgp inhibition, flow cytometric assay,

7

MDR gene

transfer into peripheral blood

progenitor cells, 873

MDRJ gene

expression, breast carcinoma, 1231

expression, endometrium, I 981

retroviral transfer, bisantrene

resistance, 973

upregulation prevention by

cyclosporin A and PSC 833, 713

MRP-mediated

modulation by acrolein and

chloroacetaldehyde. 1321

PAK-lO4P reversal, 369murine hepatoma model, 695

vulnerability to aromatic fatty acids, 865

Multidrug resistance proteingene expression, breast carcinoma, 1231

glutathione depletion and. 1961

multidrug resistance

modulation by acrolein and

chloroacetaldehyde. 1321

PAK-lO4P reversal, 369

Multiforme, glioblastomarecurrence

low-grade. biological and molecular

analysis. I 87

Multiple myelomahigh-dose melphalan. 947

MutationsAR, prostate cancer, 277

DNA mismatch repair gene, sporadic

endometrial tumors, 1907

hypoxanthine-guanine phosphoribosyl

transferase

peripheral white blood cells,

malignant melanoma treated with

dacarbazine and hydroxyurea, 303

K-ras

lung carcinoma, 41 1

non-small cell lung carcinoma, 1083

p53bladder cancer, 1055

endogenous. CTL target. 877expression, soft tissue sarcoma, I 391

molecular screening. multifocal

transitional cell carcinoma of bladder,

1795

p2 1 expression and, malignant

ovarian epithelial cells, 1571

recurring head and neck cancer, I 577

point

p53, colorectal carcinoma, 1049

Myelodysplastic syndrome

erythropoiesis stimulation by stem cell

factor, 1031

microsatelbite alterations, I 583

Myelomaall-trans retinoic acid and antireceptor

antibodies and, 253

Myeloma, multiple

high-dose melphalan, 947

N

Natural killer cells

CD3 � expression, cervical cancer, 1825

expansion by daily subcutaneous low-

dose IL-2, 669

interleukin 2 effects, metastatic cancer.

493

tumor-associated

signal transduction defects. ovarian

carcinoma, 161

Neck

Clinical Cancer Research 2067

metastases

occult, laryngeal carcinoma, I 801

Neoplasia, cervical intraepithelialmicronutrient plasma levels, 181

Neoplasms: see TumorsNeu/erbB-2

receptors

tumor cells expressing. I cell-

mediated cytolysis. 1001

Neuroblastoma

dissemination

DCC loss of expression. 1097

somatostatin receptor type 2 expression,

1757

IrkA protein detection by mAb 5C3,I 361

Neurotoxicity5-fluorouracil. dihydropyrimidine

dehydrogenase deficiency, 477

Newcastle disease virusinfected autologous tumor cell vaccine

active specific immunotherapy.

colorectal carcinoma, 21

Nitrosoureabifunctional chemotherapy with

anthracycline. bladder cancer, I 315

resistance

retroviral MGMT gene transfer,

human hematopoietic progenitors,

1353

Non-small cell lung carcinoma

advanced

paclitaxel. phase II study. 941

anti-erbB-2 effects, orthotopic human,

I 851

bel-2 protein expression. 915

chromosome 3p loss of heterozygosity.

1 185

K-ras mutations, 1083

p53 protein expression

prognostic significance. 155

retinoblastoma and. 1 169

and survival time, 915

prognosis

biological parameters. model, 1067

retinoblastoma protein expression, 1 169

TIMPI expression and adverse

prognosis. 1369

NSC 615291: see Bizelesin

Nuclear antigenproliferating cell

and occult neck metastases, laryngeal

carcinoma, 1801

truncated p2 1 adenovirus. growth

suppression. 1221

Nucleotide excision repairfludarahine-mediated inhibition

and apoptosis. quiescent lymphocytes.

I 731

0

Oligonucleotides

antisense

anti-EGF-related growth factor, colon

carcinoma, 601

c-rnvc blockade, thyroid

carcinogenesis. I 19

OLX-209: see also AR209lung cancer activity, 75

Omega-3 fatty acids

suppressive effects. breast cancer. I 751

Oncogenes: see also Genes; Proto-

oncogeneslymphokine-activated killing sensitivity

and. MCF-IOA cells, 207

Oncoprotein: see also Proteinbcl-2

expression. non-small cell lung

cancer, 915

expression, prostatic cancer, 389

expression. resectable pancreatic

adenocarcinoma, 2015

expression. T� breast cancer, 1887

-induced apoptosis. MCF-7 cells,

1215

prognostic model, non-small cell lung

carcinoma, 1067

prognostic significance. early stage

head and neck cancer after

radiotherapy. 261

p21

expression. and p53 mutation, 1571

expression, breast carcinoma, I 591

truncated adenovirus, growth

suppression, 1221

p53alterations, non-small cell lung

carcinoma, I I 69

cell death, 435

clustered immunostaining, prostate

cancer, 399

DNA damage response. tamoxifen

and. 1439

endogenous mutant, CTL target. 877

expression. breast carcinoma, 1591

expression, non-small cell lung

cancer. 155. 915

expression. resectable pancreatic

adenocareinoma, 2015

MIB-b tumor cell proliferation rate,breast carcinoma. 147

mutant expression. soft tissue

sarcoma, 1391

prognostic model, non-small cell lung

carcinoma. 1067

prognostic value, breast cancer. 2007

suramin induction, 269

Oncotoxinsanti-erbB-2

lung cancer, 75

orthotopic human lung cancer. I 851

Oral squamous carcinomaantitumor effects of cisplatin combined

with ALRIIO57, human xenografts.

511

Organotypic modeltopical gene therapy, head and neck

squamous cell carcinoma, 1659

Ornithine decarboxylase

and breast cancer prognosis, 1901

Ovarian carcinomacell motility inhibition by paclitaxel

(Taxol), 1725cyclic AMP-binding proteins. 201

immunotherapy

active, gene modification of tumor

cells. 59

p21 expression and p53 mutation, 1571

refractory

carboplatin combined with

cyclosporin A. phase II trial, 1693

refractory advanced

docetaxel, phase II study, 837

signal transduction defects. tumor-

associated lymphocytes. 161

telomerase activity. 2023tumor blood vessel markers

eosinophil peroxidase. I 867

variant and wild-type estrogen receptors.

2029

Ovarian epithelial cellsmalignant

p2 1 expression and p53 mutation.

I 571

pI6”�’

P

expression. breast cancer. 1993pJ9SRF

expression, breast cancer, I 993

p21 proteinexpression

and p53 mutation. malignant ovarian

epithelial cells. 1571

prognostic value, breast carcinoma,

1591

truncated adenovirus, growth

suppression. 1221

p53 proteinalterations, non-small cell lung

carcinoma, I 169

anti-p53 antibodies

serum, predating cancer. I 767

cell death, 435

clustered immunostaining. prostatecancer, 399

DNA damage response

tamoxifen and, 1439

expression

resectable pancreatic adenocarcinoma,

2015

gene

human papilloma virus and, head and

neck cancer, 755

mutant expression. soft tissue

sarcoma, 1391

mutations. bladder cancer. I 055. 1795

mutations, CIL target. 877

mutations. malignant ovarian

epithelial cells, 1571

mutations, molecular screening. 1795

mutations, recurring head and neck

cancer. 1577

point mutations. colorectal carcinoma,

1049

MIB-1 tumor cell proliferation rate,breast carcinoma, 147

prognostic model. non-small cell lung

carcinoma, 1067

prognostic value

breast cancer. 1591

breast cancer, validation, 2007

non-small cell lung cancer. 155, 915

suramin induction, 269

wild-type

adenoviral-mediated gene expression.

radiation sensitization, I 665

cytotoxicity potentiation, colon

cancer, I 649

dominance, colon carcinoma cells,

1639

2068 Subject Index

p107 protein

gene expression, lung cancer, 1239

Paclitaxel (see also Taxol)activity, cervical cancer, 1285

advanced non-small cell lung cancer,

phase II study, 941

-induced cell death, MDA-MG-468

cells, 847

resistance

PAK-104P reversal, 369

PAK-104PMRP-mediated multidrug resistance

reversal, 369

PALA: see N-Phosphonacetyl-L-

aspartatePancreatic adenocarcinoma

resectable

bcb-2 and p53 expression, 2015

Pancreatic carcinomahyaluronan receptor expression, 1607

Paracrine growth factorsinterleukin 6, breast carcinoma, 215

PDGF: see Platelet-derived growthfactor

Pediatric Oncology Group study

red blood cell methotrexatepharmacology, acute lymphocytic

leukemia, 311

Pediatrics: see ChildrenPenclomedine

metabolism, murine and human, 953

tissue and tumor distribution. rats, 541

Peptidesgrowth factors

cisplatin-induced cell death

modulation, ovarian cancer, 1307

Periepithelial stromaPDGF 13 receptor, breast carcinoma, 773

Peripheral bloodleukocytes

platinum-DNA adducts, ICP-MS

quantitation, 1829

lymphocytes

CD3 � expression, cervical cancer,1825

mononuclear cells

dihydropyrimidine dehydrogenase

activity, 507

progenitor cellsimmunomagnetic purging, breast

cancer, 81

MDR transfer into, 873

white blood cells

dacarbazine-induced DNA damage.

malignant melanoma, 303Peritoneal drug exposure

after intraperitoneab administration

vasopressin and, 3 1 1

P-glycoproteininhibition

GG918, flow cytometric assay, 7serum bioassay, 403

Pharmacokineticscarboplatin with paclitaxel, 549

carzelesin, 1717

gemeitabine, small cell lung cancer, 359

high-dose melphalan, multiple myeloma,

947

intraperitoneal drugs

vasopressin and, 3 1 1

tegafur combined with uracil, 1461

Phenylacetatemubtidrug resistance vulnerability, 865

Phenylbutyrate

apoptosis induction, prostate cancer, 379

multidrug resistance vulnerability, 865

Phorbol ester tumor promotergrowth inhibition, glioblastoma, 1017,

1638

N-Phosphonacetyl-L-aspartatecombined with fluorouracil and

dipyridamole, advanced cancer, 1 107

PIXY321effects on human tumor colony-forming

units, 1713

PKC: see Protein kinase CPlacental site trophoblastic tumor

molecular analysis and clinical

experience, 897

Plasmacyclosporin A chemosensitization, post-

liver transplant, 531

drug exposure

intraperitoneal, vasopressin and, 3 1 1

estrogen

suppression by megestrol acetate,

postmenopausal breast cancer, 1515

micronutrient levels, cervical

intraepithelial neoplasia and cancer,

181

topotecan study, 1489

Platelet-derived growth factor

13receptors, breast carcinoma, 773Platinum

combined with cyclosporin A, refractory

ovarian and fallopian tube cancer,

1693

DNA adducts

advanced germ cell cancer, 1063ICP-MS quantitation. peripheral blood

beukocytes, 1829

head and neck cancer chemotherapy,

GST staining and, 1859refractory advanced ovarian carcinoma

docetaxel, phase II study, 837

pml/RAR-a hybrid proteinimmune recognition, acute

promyeloeytic leukemia, 593

Poly(ADP-ribose) polymerasegene expression

and genomic instability, breast cancer,

1 163

Polyamine analogues-induced cell death, lung tumor cells,

441

Polymerase chain reactionreverse transcription-

MDRJ expression, endometrium,

1981

somatostatin receptor type 2

expression, neuroblastoma, 1757

Positron emission tomography

FDG and FES, breast cancer, 933Progenitor cells

hematopoietic

breast cancer treatment failure, Her2/

nez� overexpression. 1509

retroviral MGMT gene transfer, 1353

peripheral blood

immunomagnetie purging, breast

cancer, 81

MDR transfer into. 873

Progesterone

receptors

gene methylation. breast tumors, 805

Proliferating cell nuclear antigen

and occult neck metastases, laryngeal

carcinoma. 1801

truncated p2 1 adenovirus

growth suppression, 1221

Proliferative breast diseasevascularity. 1873

Prostate-specific antigen-producing prostatic carcinoma

xenograft LuCaP 23. characterization.

1039

Prostate-specific membrane antigenfolate hydrolase, prostatic carcinoma

cells, 1445

Prostatic carcinomaandrogen and glucocorticoid receptors,

889

apoptosis

phenylbutyrate induction. 379

AR gene mutations, 277

bcl-2 protein expression. 389

chromosomal aneusomies. prognostic

value, 137

clustered p53 immunostaining. 399

hormone-refractory

�#{176}Y-CYT-356 treatment, 1289

metastatic variants, orthotopic

implantation in nude mice, 1627

progression

trisomy 7 marker, 1553

prostate-specific membrane antigen

folate hydrolase. 1445

TGF-�3l receptor expression. 1255

TGF�3R-II levels, 635xenografts

LuCaP 23. characterization. 1039

Prostatic hyperplasiaandrogen and glucocorticoid receptors.

889

Proteases

prognostic markers. 613

Protein: see also Oncoprotein

anti-GD2-IL2

effector cell activation, I 95 1

bcl-XL

-induced apoptosis. MCF-7 cells.

1215

CD44

mRNA isoforms, thyroid and breast

carcinoma, 1251

cyclic AMP-binding. ovarian cancer,

201

Glut 1

overexpression, colorectal

carcinogenesis, 1 15 1

glycoprotein 75

cell surface target. melanoma, 1837

GM-CSF/IL-3

effects on human tumor colony-

forming units, 1713

keratin 18

expression. breast cancer, 1879

K-sam

immunohistochemical detection,

stomach cancer, I 373

low molecular weight

MHC class I and, renal cellcarcinoma. 1427

- alkyltransferase, malignant colon, 577

Quercetin

phase I clinical trial, 659

R

Radiationcytotoxicity

potentiation by wild-type p53, colon

cancer, 1649

Clinical Cancer Research 2069

melanosomal

cell surface target, 1837

multidrug resistance

gene expression. breast carcinoma,1231

glutathione depletion and, 1961

multidrug resistance, PAK-104P

reversal, 369

P-glycoproteininhibition, serum bioassay, 403

inhibition by GG9I8, flow cytometric

assay, 7

pml/RAR-a

immune recognition. acutepromyelocytie leukemia, 593

retinoblastoma

alterations, non-small cell lung

carcinoma, 1169

signal-transducing

defects, tumor-associated

lymphocytes, ovarian carcinoma, 161

INF-Bl(Fv)cytotoxie and antitumor activity, Le”antigen-expressing cells, 1523

IrkAdetection by mAb 5C3,

neuroblastoma, I 361

Protein kinase A

subunits

lymphokine-activated killing

sensitivity and, MCF-1OA cells, 207

Protein kinase Cinhibitor CGP 41251

growth inhibition, glioblastoma, 1017,1638

signal transduction pathway

drug-induced apoptosis modulation,

1915

Protein tyrosine kinaseppfj�JC�SrC

activation, colorectal carcinoma liver

metastases, 1397

pp62�e�

activation, coborectal carcinoma liver

metastases, 1397

Proto-oncogenesc-myc

overexpression, eoloreetal carcinoma,

1049

PSC 833prevention of MDR1 upregulation, 713

Purgingimmunomagnetie

peripheral blood progenitor cells,

breast cancer, 81

Pyrimidine

urinary levels, 1937

local

combined with lL-2, murine renal

carcinoma, I 543

sensitization by adenovirus wild-type

PS3, coloreetal cancer, 1665Radiosensitivity

hypericin-enhaneed. malignant glioma

cells, 843

Radiosensitization

5-fluorocytosine. colorectal carcinoma.

53

5-iododeoxyuridine

leucovorin modulation, phase I study,1299

Radiotherapyearly stage head and neck cancer

bcl-2 protein. 261

head and neck cancer

p53 mutations, 1577

Receptorsandrogen

gene mutations, prostate cancer, 277

prostatie hyperplasia and carcinoma,

889

anti-IL-6, antibodiescombined with retinoids, myeloma,

253

anti-If, antibodies

combined with retinoids, myeloma,

253

epidermal growth factor

expression, metaplastic bronchial

epithelium, 1787

gene amplification, esophageal

squamous cell carcinoma. 909

erbB-3

tumor cells expressing, I cell-

mediated cytolysis, 1001

erbB-4tumor cells expressing. I cell-mediated cytolysis, 1001

estrogen

FES-PET and, breast cancer, 933

gene methylation, breast tumors, 805

mRNA bevels, breast cancer, 923

status, angiogenesis determination

and, 1191

variant and wild-type, ovarian

carcinoma. 2029

folatedietary folate and, neoplastic murine

tissue, 1135

glucocorticoid

prostatic hyperplasia and carcinoma,

889

hyaluronan

expression. pancreatic cancer cells,

1607

insulin-like growth factor I

regulation by ICI 182780, 2037

interleukin 1

antagonist induction after IL- I

therapy, 501

laminin, Mr 67,000

expression, thyroid cancer, 1777NeulerbB-2

tumor cells expressing, I-cell-mediated cytolysis, 1001

platelet-derived growth factor �3,

breast carcinoma, 773

progesterone

gene methylation. breast tumors, 805

9-cis-retinoic acid

combined with cisplatin. human oral

squamous carcinoma xenografts. 5 1 1

phase I trial, 471phase I trial, solid tumors, 287

13-cis-retinoie acid

antiproliferative effects. renal cellcarcinoma, 1077

high-dose. recurrent malignant glioma

treatment, I 931all-trans-retinoie acid

apoptosis induction, head and neck

squamous cell carcinoma cell lines.

855

combined with antireceptor

antibodies, myeloma and. 253

retinoic acid, �

expression, renal cell carcinoma, 1077somatostatin, type 2

gene expression. neuroblastoma, 1757steroid

prostatie immunohistochemistry, 889

I-cell

13 variable region, melanoma afterimmunotherapy, 767

transforming growth factor �

type II, prostate cancer, 635transforming growth factor �3 I

loss of expression. prostate cancer,

I 255IrkA

protein detection by mAb 5C3,

neuroblastoma, 1361tumor necrosis factor

recombinant human lgG chimera,combined with IL-2. 1341

vascular endothelial growth factor

(KDR)

intestinal-type gastric cancer, I 679

Red blood cellsglucose transporter

overexpression, colorectal

carcinogenesis, 1151

methotrexate pharmacology. acuteIymphocytie leukemia in children.331

Renal carcinomalocal tumor irradiation combined with

IL-2 therapy, murine, 1543

Renal cell carcinomaIL- 13 antitumor effects, 1743MHC class I, LMP, and TAP genes,

1427

I 3-cis-retinoic acid antiproliferativeeffects. 1077

retinoic acid receptor �3 expression.

1077

Renal failurehigh-dose mebphaban autotransplants.

947

Replication errorshematological neoplasia. 1583

Resistance: see Drug resistanceRetinoblastoma

gene family expression, lung cancer,I 239

intraocular

chemotherapy combined with

eyelosporin, 1499

2070 Subject Index

protein alterations, non-small cell lungcarcinoma, I I 69

Retinoic acidreceptor 13

expression, renal cell carcinoma, 10779-cis-Retinoic acid

combined with cisplatinantitumor effects, human oralsquamous carcinoma xenografts, S I 1

phase I trial, 471phase I trial. solid tumors, 287

13-cis-Retinoic acid

antiproliferative effects, renal cell

carcinoma, 1077

high-dose

recurrent malignant glioma treatment,1931

all-irans-Retinoic acidapoptosis induction, head and neck

squamous cell carcinoma cell lines,

855

combined with antireceptor antibodiesmyeloma and, 253

Retinolplasma levels, cervical intraepithelial

neoplasia and cancer, I 81Retroviral gene transfer

MDRinto peripheral blood progenitor cells,873

MGMT, human hematopoieticprogenitors, 1353

Reverse transcription-polymerase chainreaction

MDRI expression, endometrium, 1981somatostatin receptor type 2 expression.

neuroblastoma, 1757Rhabdomyosarcoma, colon

therapyirinotecan combined with 5-

fluorouracil or etoposide. xenograftmodels, 107

RHAMM

expression. pancreatic carcinoma, 1607

Ricin A chain-containing immunotoxin treatment

serum fibronectin levels, 1705

RNA

breast carcinoma content, 419TIMPJ expression

and adverse prognosis, non-small celllung cancer, I 369

S

Sarcoma, soft tissuemutant p53 expression, 1391

Serumanti-p53 antibodies, predating cancer,

1767

autologous, combined with stem cellfactorerythropoiesis stimulation,

myebodysplastic syndrome, 1031

cytokine levels, lung cancer, 553fibronectin levels, immunotoxin therapy,

1705

P-glycoprotein inhibition, bioassay, 403

tumor marker

half-life, germ cell tumors, 1565

vascular endothelial growth factorlevels, 821

Severe combined immunodeficiencyB-cell precursor leukemia

B43-PAP plus cytosine arabinosidetreatment, mice, 1533

multidrug resistance, murine hepatoma

model, 695

Signaling moleculesI-cell activity, metastatic melanoma,

1263

Signal-transducing proteinsdefects

tumor-associated lymphocytes.

ovarian carcinoma, 161

Small cell carcinoma, lunggemcitabine pharmacokinetics and

metabolism, 359second lung cancer, genetic analysis,

I 103

Soft tissue sarcomamutant p53 expression, I 391

Solid tumors9-cis retinoic acid, phase I trial, 287

Solid tumors, breast

batimastat growth inhibition, mice, 1207omega-3 fauy acid suppressive effects.

1751

Somatostatinreceptor type 2

gene expression, neuroblastoma, 1757

S-phase fractionprognostic value, axiblary node-negative

breast cancer, 585Squamous cell carcinoma, cervical

advanced or recurrent

paclitaxel activity, 1285

Squamous cell carcinoma, esophagealcyclin A overexpression, 1781

cyclin Dl gene amplification, INM-

Gene, 1155EGFR gene amplification. 909

Squamous cell carcinoma, head andneck

antitumor effects of cisplatin combinedwith ALRI1O57, human xenografts,

511

apoptosis by ATRA and 4HPR, 855

cytotoxic therapytumor cell proliferation, 1453

early stageradiotherapy, bcl-2 protein andprognostic significance after, 261

growth stimulation by interleukin 4, 127

human papilboma virus and p53, 755microsatellite alterations at llp loci, 903

recurring

p53 mutations, 1577topical gene therapy, organotypic model,

1659Squamous cell carcinoma, laryngeal

cyclin Dl gene amplification, 175tebomerase activity, 1895

Squamous cell carcinoma, lung‘31I-labeled EGF radiolocalization, 13

prognostic markers

thrombomodulin, 763

Squamous cell carcinoma, oralantitumor effects of cisplatin combined

with ALRI1O57, human xenografts,

511

ST-4 cellsthioredoxin, 427

Stem cell factor

erythropoiesis stimulation,

myelodysplastie syndrome, 1031

Steroidsreceptors, prostatic

immunohistochemistry, 889

Stomach cancer: see Gastric carcinomaStreptozocin

combined with carmustine, refractorymelanoma, I I 29

resistance

MGMI and, brain tumor cell lines,735

Stromaandrogen and glucocorticoid receptors,

prostatic hyperplasia and carcinoma,

889

periepithelial

PDGF 13 receptor, breast carcinoma,773

Sulindaccombined with 5-FU and levamisole,

colon carcinoma, 37

Superficial bladder cancerprogression

p53 mutations and, 1055

Suramin

p53 protein induction, 269

T

Tamoxifenadjuvant therapy

node-positive breast cancer. predictors

ofouteome, 1191endometnal carcinoma and, 223high-dose

recurrent malignant glioma treatment,

619-induced apoptosis

modulation by HER2 overexpression,MCF-7 cells, 1215

and p53 DNA damage response, 1439

Taxolantiangiogenic activity. 1843

earboplatin pharmacokinetics with, 549

cell motility inhibition, ovarian

carcinoma, 1725

I cellsCD8�

GM-CSF release, melanoma I-cellepitope detection and. 87

cytotoxie

mutant p53-specific, lung cancer

cells, 877

epitopes

melanoma, detection, 87leukemia, adult

-derived factor, cisplatin resistance,

427

-mediated tumor cell lysis. 1001

peripheralCD3 � expression, cervical cancer,1825

receptor-13

repertoire, melanoma after

immunotherapy, 767recognition of pml/RAR-a, acute

promyelocytic leukemia, 593

Clinical Cancer Research 2071

signaling deficiency, metastatic

melanoma, I 263

tumor-associated

signal transduction defects, ovarian

carcinoma, 161

Te: see 3-Ethyl-3’-methyl-thiatelluracarbocyanine iodide

Tegafur

combined with uracib, phase I and

pharmacokinetic study. 1461

Tellurium-containing cyanine

anticareinoma activity. mitochondria.

I 335

Telomeraseactivity. gynecological tumors, 2023

acute myelogenous leukemia activity.

799

bladder cancer activity. 929

laryngeal squamous cell carcinoma

activity, 1895

Temozolomideresistance

MGMT and, brain tumor cell lines,735

Tenascinantitenascin 81C6 mAb

intrathecal ‘31I-labeled, phase I trial

therapy, 963

l2-O-Tetradecanoylphorbol-13-acetategrowth inhibition. glioblastoma, 1017.

I638

TGF-132: see Transforming growthfactor 132

TGF: See Transforming growth factorThioredoxin

cisplatin resistance, 427

Three-dimensional ‘9F magneticresonance spectroscopy

hepatic 5-fluorouracil catabolism

quantitation, 339

Thrombomodulinprognostic value, lung cancer, 763

Thymidylate synthaseinhibition

fluoropyrimidine efficacy and, colon

26-B tumors, 1327

inhibitors

AG331, phase I trial. 1685

folate analogues, 227

Thyroid carcinomaCD44 mRNA isoforms. 1251

c-mvc overexpression. 1 19

Mr 67.000 expression. 1777

Tissue‘4C-penclomedine distribution, rats, 541

Tissue inhibitor of metalloproteinaseRNA expression

and adverse prognosis, non-small cell

lung cancer, 1369

I lymphocytes: see 1 cellsTNF-a: see Tumor necrosis factor a

TNM-Gene

cyclin Dl gene amplification, squamous

cell carcinoma of esophagus, 1 155

a-Tocopherolplasma levels, cervical intraepithelial

neoplasia and cancer, I 81

‘r-Tocopherolplasma levels, cervical intraepithelial

neoplasia and cancer. I 81

Topotecanphase I trials, 1489

leukemia, 1921

total

AUC curve, limited sampling model,43

Toxicity: see also Cytotoxicity;

Hematotoxicity; Neurotoxicity

daily subcutaneous low-dose IL-2, 669

high-dose melphalan. multiple myeloma,

947

Toxins: see Immunotoxins; OncotoxinsTransferrin

anti-If receptor antibodies

combined with retinoids, myeloma

and, 253

and resistance to gallium nitrate,

lymphoid leukemie cells, 1009

Transforming growth factor 13receptor type II, prostate cancer, 635

Transforming growth factor 131

receptors

loss of expression. prostate cancer,

1255

Transforming growth factor 132secretion

stimulation by TNF-a. MCF-7 cells,

827

Transitional cell carcinomarecurrence

detection. clonality and, 1795

Transitional cell carcinoma, bladder

multifocal

molecular screening with p53

mutations, I 795

progression

p53 mutations and, 1055

Transplantation, livercyclosporin A chemosensitization, post-

liver transplant patient plasma. 531

Transplantsautotransplants

high-dose melphaban. renal failure.

947

Transporters associated with antigenprocessing

gene expression

MHC class I and, renal cellcarcinoma, 1427

Trisomy 7

prognostic significance. prostate cancer,

1553

Trisomy 12

chromosome 13ql4 deletions and, B-cell

chronic lymphocytic leukemia. 1673

TrkA proteindetection by mAb 5C3, neuroblastoma,

1361

Trophoblastic tumors

placental site

molecular analysis and clinical

experience. 897

Tumor antigen genesexpression, gastric carcinoma. 1619

Tumor-associated lymphocytes

signal transduction defects, ovarian

carcinoma, 161

Tumor blood vesselscounts, intestinal-type gastric cancer,

1679

eosinophil peroxidase. ovarian and

endometrial cancers, 1867

Tumor cell proliferationcytotoxic therapy, head and neck

tumors, 1453

prognostic significance, breast

carcinoma. 147

Tumor cellschemosensitivity

enhancement by gene therapy. 1089

death

apoptotie, and chemosensitivity, 623

HSV-IK DNA and gancicbovir. 47

lymphocytes. 785

gene modification

active immunotherapy. breast and

ovarian cancer, 59

growth suppression by truncated p21

adenovirus, 1221

lysis

I-cell-mediated, 1001

mubtidrug-resistant

vulnerability to aromatic fatty acids,

865

Tumor colony-forming unitsPIXY32I effects, I 713

Tumor markerseosinophil peroxidase. ovarian and

endometrial cancers, 1867

serum

half-life, germ cell tumors, 1565

Tumor necrosis factorreceptors

recombinant human IgG chimera.

combined with IL-2. 1341

Tumor necrosis factor astimulation of IGF-132 secretion, MCF-7

cells, 827

INF-Bl(Fv) fusion protein. cytotoxicand antitumor activity. 1523

Tumor promotersphorbol ester

growth inhibition. glioblastoma, 1017.1638

Tumors‘4C-penclomedine distribution. rats, 541

folate receptor expression

dietary fobate and, murine, 1 135

growth suppression by IL-b,

melanoma, 1969growth suppression by truncated p21

adenovirus, 1221

somatostatin receptor type 2 expression.

I 757

TNF-Bl(Fv) fusion protein antitumoractivity. 1523

Tumors, bladderdoxorubiein pharmacodynamies. 1275

Tumors, brainmethylator resistance

MGMI and, 735resection cavities with subarachnoid

communication

intrathecal 31 I-labeled 8 1C6 mAbtherapy, phase I trial, 963

Tumors, breastER and PR gene methylation, 805

Tumors, colonfluoropyrimidine efficacy and

thymidylate synthase inhibition, I 327

Tumors, coborectal

2072 Subject Index

apoptosis, 1999Tumors, endometrial

sporadic

DNA mismatch repair genes, 1907Tumors, germ cell

metastatic nonseminomatousserum tumor marker half-life, 1565

Tumors, gynecologicaltelomerase activity, 2023

Tumors, head and neckcytotoxic therapy

tumor cell proliferation, 1453Tumors, hematobogical

replication errors, 1583Tumors, leptomeningeal

intrathecal ‘31I-labeled 8lC6 mAb

therapy, phase I trial, 963Tumors, liver

regional chemotherapy

chemosensitivity-directed, prospective

decision-aiding trial, 1469

Tumors, lungcathepsins, 561

malignant

inhaled nIL-2, phase I trial, 1115polyamine analogue-induced cell death,

441

Tumors, mesenchymabMel-CAM immunoreactivity, 569

Tumors, solidbreast

batimastat growth inhibition, mice,

1207

omega-3 fatty acid suppressive

effects, 17519-cis retinoic acid, phase I trial, 287

Tumors, trophoblasticplacental site

molecular analysis and clinicalexperience, 897

Tumor suppressor genes: see also GenesDCC

loss of expression, disseminated

neuroblastoma, 1097

expression, breast cancer, 1993�J9ARF

expression, breast cancer, 1993

p53endogenous mutant CIL target, lung

cancer cells, 877

human papilloma virus and, head andneck cancer, 755mutations, bladder cancer, 1055

mutations, p21 expression and, 1571

mutations, recurring head and neck

cancer, 1577

point mutations, colorectal carcinoma,1049

Tyrosine kinaseinhibition by quercetin, phase I clinical

trial, 659

U

U-7779: see BizelesinU-80244: see CarzelesinUCN-01: see 7-HydroxystaurosporineUFT

phase I and pharmacokinetic study,

1461Uracil

combined with tegafur, phase I and

pharmacokinetic study, 1461

Urineirinotecan metabolites, 1943

pyrimidine levels, 1937

Urokinase plasminogen activatorprognostic significance, breast cancer,

613

V

VaccinesBEC2 anti-idiotypic

immunization, melanoma, 679

Newcastle disease virus-infected

autobogous tumor cell

active specific immunotherapy,

colorectal carcinoma, 21Vascular endothelial growth factor

intestinal-type gastric cancer, 1679

mRNA expression, lung cancer, 141 1

receptor (KDR)intestinal-type gastric cancer, 1679

serum levels, 821

Vascubarityproliferative breast disease and

carcinoma in situ, 1873

Vascular leak syndromeserum fibronectin levels and,

immunotherapy, 1705

Vasopressinand intraperitoneal drug

pharmacokinetics, 31 1

Vessel countsintestinal-type gastric cancer, 1679

VimentinMIB-l tumor cell proliferation rate,

breast carcinoma, 147

Viruses

human papilloma

and p53, head and neck cancer, 755

Virus-free gene transfer

HSV-IKcombined with gancielovir,

melanoma, 47

w

White blood cellsperipheral

dacarbazine-induced DNA damage,

malignant melanoma, 303

Whole bloodPgp inhibition, flow cytometric assay, 7

Wild-type estrogen receptorovarian carcinoma, 2029

Wild-type p53cytotoxicity potentiation, colon cancer,

1649

dominance, colon carcinoma cells, 1639

gene expression

adenoviral-mediated, radiation

sensitization, 1665

x

Xenografts

colon adenocareinoma orrhabdomyosareoma

irinotecan combined with 5-

fluorouracib or etoposide, I 07

colon carcinoma

5’-AdThd modulation of IdUrdmetabolism, 981

hepatocellular carcinoma

multidrug resistance, murine model,

695

MRP-mediated multidrug resistance

PAK-104P reversal, 369

oral squamous carcinomaantitumor effects of cisplatin

combined with ALRIIOS7, 511

prostatic carcinoma

LuCaP 23, characterization, 1039

Y

�#{176}Y-CYT-356hormone-refractory prostate cancer

treatment, 1289

Clinical Cancer Research

Submit papers directly to one of the six Senior Editors, each of whom

is responsible for a particular area of research. Senior Editors will

Instructions for AuthorsScope

Clinical Cancer Research, a journal of the American Association for

Cancer Research, publishes original articles describing clinical research onthe cellular and molecular characterization, prevention, diagnosis, and ther-

apy of human cancer. Its focus is on innovative clinical research and

translational research which bridges the laboratory and the clinic. Clinical

Cancer Research is especially interested in clinical trials evaluating new

treatments for cancer, research on molecular abnormalities that predict

incidence, response to therapy, and outcome; and laboratory studies of new

drugs and biological agents that will lead to clinical trials in patients.Specific areas of interest include clinical and translational research in:

molecular pharmacology and chemotherapy; drug sensitivity and resist-

ance; tumor immunology and immunotherapy; radiobiobogy and radiation

oncology; solid tumor oncology; hematological malignancies; surgical on-

cology; pediatric oncology; molecular oncology and cancer genes; pathol-

ogy, markers, and prognostic indicators; growth factors, cytokines, and

signal transduction; bone marrow transplantation; gene therapy; cancer

endocrinology; cell adhesion, invasion, and metastasis; prevention of pri-

mary and recurrent cancer; differentiation and cell death; clinical genetics;

and detection of minimal disease.

Editorial Policy

When a manuscript is received for consideration, the Editors assume

that no similar paper has been or will be submitted for publication

elsewhere. Further, it is understood that all authors listed on a manu-

script have agreed to its submission. The signature of the corresponding

author on the letter of submission signifies that these conditions have

been fulfilled.

Journal policy requires that authors, reviewers, Associate Editors, and

Senior Editors reveal in a letter to the Editor-in-Chief any relationships that

they have that could be construed as causing a conflict of interest with

regard to a manuscript under review. The letter should include a statement

of any financial relationships with commercial companies involved with aproduct under study.

Upon acceptance, authors must transfer copyright to the American

Association for Cancer Research, Inc., the copyright owner of the

journal, prior to publication. Once an article is accepted for publication

in Clinical Cancer Research, the information therein is embargoed from

reporting by the media until the mail date of the issue in which the

article appears.

The Editors endorse the principles embodied in the Declaration of

Helsinki and expect that all investigations involving humans will have beenperformed in accordance with these principles. To obtain a copy of the

Helsinki Declaration, please contact the World Medical Association, 28,

Ave. des Alpes, F-012l0, Femey-Voltaire, France. For animal experimen-

tation reported in the journal, it is expected that investigators will have

observed the Interdisciplinary Principles and Guidelines for the Use ofAnimals in Research, Testing, and Education issued by the New York

Academy of Sciences’ Ad Hoc Committee on Animal Research, a copy ofwhich is available for $5.00 from the Marketing Department, New York

Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All

human and animal studies must have been approved by the investigator’s

Institutional Review Board.

conduct the review process with the expert assistance of the journal’s

Associate Editors, will correspond with authors about their manuscripts,

and will make editorial decisions regarding publication. Papers within

the subject areas covered by the Editor-in-Chief, as well as manuscripts

that do not pertain to any of the research areas listed, should be

submitted to Dr. Mendelsohn. Research areas, mailing addresses, and

telephone and fax numbers for the Editor-in-Chief and Senior Editors

can be found at the end of these Instructions.

Submit four original sets (not photocopies) of figures along with fourcopies of the manuscript. If a manuscript is closely related to papers that are

in press or have been submitted elsewhere, please provide copies of those

papers with your submission. For both original and revised submissions,we cannot guarantee that manuscripts and illustrations will be re-

turned to the author.The letter of submission can suggest the Associate Editors who might

serve as reviewers of the manuscript. In addition, we invite authors to

provide the names, addresses, and telephone/fax numbers of other potential

reviewers who are not current or recent collaborators or advisors in the areaunder investigation.

Advances in Brief will be reserved for concise, defmitive reports of

novel observations and discoveries that have unusual importance. A request

for consideration for Advances in Brief should be included in the letter of

submission. A Minireview is a briefanalysis (typically 3-4 printed pages) of

a focused, timely research topic, aimed at a multidisciplinary audience.Minireviews and Controversies in Clinical Cancer Research that are sub-

mined or solicited will undergo editorial review. The Editors welcome

Letters to the Editor, which will be published if they are determined to be

appropriate.

FormatManuscripts must be written succinctly in clear, grammatical English.

Define abbreviations in an inclusive footnote to the text. Double-space

on 8 1/2 x I 1-inch paper. Dot-matrix printing is not acceptable. The

format is as follows:

1 . Title page, including title, authors and their institutions, research

support, and address plus telephone/fax numbers of the correspond-

ing author;

2. A running title of fewer than 50 characters;

3. Three to five key words that do not appear in the title;

4. Abstract, of not more than 250 words, stating briefly the objectives,

methods, results, and conclusions of the study;

5. Text arranged in this order: Introduction, Methods, Results, Discus-

sion, Acknowledgments, References;

6. Footnotes, on a page separate from the text. Designate footnotes

consecutively with superscript Arabic numerals;

7. Tables, on pages separate from the text, with descriptive titles and

legends that make the data understandable without reference to the

text;8. Figure legends, on pages separate from the text, with descriptive

titles and explanations to make the data understandable without

reference to the text. Define all symbols and include staining forhalftones where applicable;

9. Figures.

Review Process

The review process, expedited by fax transmission and overnight mailservice, is conducted as rapidly as possible. Each submitted manuscript

is reviewed by at least two experts in the field of investigation. If the

authors are invited to submit a revised manuscript for an expeditedfurther review, the revised version must be submitted within three

months.

Manuscript Submission

References

Include only those articles that have been published or are in press.

Unpublished data or personal communications must be cited as foot-

notes to the text. Personal communications should be substantiated by a

letter of permission. Number references in the order of their first

mention in the text. Cite only the number assigned to the reference.

References must be double-spaced.

SAMPLE REFERENCES:

1. Shaffer, D. W., Smith, L. S., Burns, H. A., Clark, G. M., Eckardt, J. R.,

Fields, S. M., Weiss, G. R., Rinaldi, D. A., Bowen, K. J., Kuhn, J. G., and

Von Hoff, D. D. A randomized phase I trial of chronic oral etoposide with

ii Instructions for Authors

or without granulocyte-macrophage colony-stimulating factor in patientswith advanced malignancies. Cancer Res., 53: 5929-5933, 1993.

2. Dimaggio, J. J., Scheinberg, D. A., and Houghton, A. N. Monoclonal

antibody therapy of cancer. In: H. M. Pinedo, B. A. Chabner, and D. L.Longo (eds.), Cancer Chemotherapy and Biological Response ModifiersAnnual, Vol. 1 1, pp. 177-203. Amsterdam: Elsevier Science Publishers

B.V., 1990.

Figures

Provide four original sets of figures (whether line-cut draw-ings or halftones). Each sorted set should be in a separate labeledenvelope, for distribution to reviewers. A typed label placed on thereverse side of each figure should contain the first author’s name, figurenumber, and an arrow indicating top of figure. Letters and numbers onfigures should not be smaller than 6-point or larger than 12-point type.

All figures will be published at a width ofapproximately 3 inches (8 cm)unless the author requests a greater width. Use tissue overlays toindicate important areas of the photographs that must be reproducedwith greater fidelity.

Authors are encouraged to submit color figures. The expense of

reproducing color photographs must be offset partially by the author. In

1996, the cost of color reproduction charged to authors will be $975 per

color figure. Submit color figures on flexible backing.

Proofs

Page proofs must be returned to the office of the American Association for

Cancer Research within 24 hours of receipt. Return proofs by overnightmail. Proofs not received by the deadline will be published without the

authors’ corrections. Accepted manuscripts are regarded as final copy and

should not be altered substantially in proof. Extensive alterations couldcause publication delays, and authors will be charged for excessive alter-ations in proof.

Typesetting Manuscripts from Computer Disks

Clinical Cancer Research welcomes disks to expedite production ofaccepted manuscripts. If your article is accepted for publication, you

will receive instructions regarding disk submission. It is the author’s

responsibility to ensure that the material on the disk matches the final

accepted version of the manuscript.

Research Areas of the Editor-in-Chief and Senior Editors

John Mendelsohn, M.D.Department of Educational Publishing Services-227The University of lexas M. D. Anderson Cancer Center1515 Holcombe BoulevardHouston, TX 77030Telephone: 713-792-6014Fax: 713-792-6016E-mail: jmendelsohn@notes.mdacc.tmc.edu

Cell proliferation and death-preclinical, and clinical trials: radiation

therapy, surgery, and subspecialty investigation

Waun Ki Hong, M.D.

Department of Thoracic/Head & Neck Medical OncologyThe University of Texas M. D. Anderson Cancer CenterBox 801515 Holcombe Boulevard

Houston, TX 77030

Telephone: 713-792-6363

Fax: 713-796-8655

E-mail: waun_hong@isqm.mda.utl’.tmc.eduClinical trials targeted at specific malignancies, chemoprevention

Lance A. Liotta, M.D., Ph.D.

Laboratory of Pathology

National Cancer Institute

Building 10, Room 2A33

National Institutes of Health

10 Center Drive, MSC 1500

Bethesda, MD 20892-1500

Telephone: 301-496-3185Fax: 301-402-0043

E-mail: lance@helix.nih.gov

Pathology, metastasis

David Sidransky, M.D.

Otolaryngology/Head & Neck Cancer Research

Johns Hopkins University

818 Ross Research Building

720 Rutland Avenue

Baltimore, MD 21205-2196

Telephone: 410-550-5153

Fax: 410-614-1411

E-mail: dsidrans@welchlink.webch.jhu.edu

Molecular pathogenesis, molecular correlates

Paul Sondel, M.D., Ph.D.Departments of Pediatrics, Human Oncology, & Genetics

University of Wisconsin Clinical Science Center

K4/448

600 Highland Avenue

Madison, WI 53792Telephone: 608-263-9069

Fax: 608-263-4226E-mail: pmsondel@facstaff.wisc.edu

Immunotherapy and cytokines-preclinical, and clinical trials

David R. Spriggs, M.D.

Developmental Chemotherapy Service

Memorial Sloan-Kettering Cancer Center1275 York Avenue

New York, NY 10021

Telephone: 212-639-2203Fax: 212-717-3272E-mail: dspriggs@pop.ski.mskcc.org

Preclinical pharmacology, pharmacological clinical trials

Jeffrey M. Trent, Ph.D.

Laboratory of Cancer Genetics

National Center for Human Genome Research

National Institutes of Health

Building 49, Room 4A22

49 Convent Drive, MSC 4470Bethesda, MD 20892-4470

Telephone: 301-402-2023

Fax: 301-402-2040E.mail: jtrent@nchgr.nih.gov

Genetics, cytogenetics

For more information, contact:

John Mendelsohn, M.D., Editor-in-Chief, Clinical Cancer Research,

Department of Educational Publishing Services-227, The University of

Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard,Houston, IX 77030, Telephone 713-792-6014, Fax 713-792-6016

or:

Publications Department, American Association for Cancer Re-

search, Public Ledger Building, Suite 816, 150 South IndependenceMall West, Philadelphia, PA 19106-3483, Telephone 215-440-9300,

Fax 215-440-9355.

AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Co-Sponsored by the Joint Section on Tumors of the American Association of

Neurological Surgeons and Congress of Neurological Surgeons

Cancer of the Central Nervous System

June 7-11,1997Loews Coronado Bay Resort

San Diego, CA

CONFERENCE CO-CHAIRPERSONS

Webster K. Cavenee I La Jolla, CA Peter McL. Black I Boston, MA

PROGRAM COMMITTEE

William F. Chandler I Ann Arbor, Ml Mark D. Noble I Salt Lake City, UTJoseph Piepmeier I New Haven, CT Bernd R. Seizinger I Boston, MA

Jean V. J. Wang I La Jolla, CA

CONFERENCE PROGRAM

Keynote AddressCharles B. Wilson I San Francisco, CA

Triumphs and Challenges of PresentDiagnosis and Management

Catherine Dumas-Duport I Paris, FrancePeter McL. Black I Boston, MAJay S. Loeffler I Boston, MAVictor A. Levin I Houston, TX

Neurobiology and DevelopmentalBiology

Fred H. Gage I La Jolla, CA

Mark D. Noble I Salt Lake City, UT

Genetic Predispositions to CNS TumorsJean V. J. Wang I La Jolla, CALawrence A. Donehower I Houston, TXEric C. Holland I Bethesda, MD

Molecular GeneticsDavid N. Louis I Boston, MAHuei-Jen Su Huang I La Jolla, CAOtmar D. Wiestler I Bonn, Germany

New Targets for TherapyMark L. Rosenblum I Detroit, MlDavid Hockenberry I Seattle, WAJerry W. Shay I Dallas, TX

Receptor Mediated Growth ControlCharles D. Stiles I Boston, MA

Webster K. Cavenee I La Jolla, CALewis T. Williams I San Francisco, CA

Novel TherapiesXandra 0. Breakefield I Boston, MAJackson B. Gibbs I West Point, PAJudah Folkman I Boston, MAFrank McCormick I San Francisco, CA

ADDITIONAL SPEAKERS TO BE ANNOUNCED

Application Deadline: March 14, 1997

Information and Application Forms:American Association for Cancer ResearchPublic Ledger Building, Suite 816150 South Independence Mall WestPhiladelphia, PA 19106-348321 5-440-9300 21 5-440-931 3 (FAX)E-mail: aacr@aacr.orgWebsite: http://www.aacr.org

Hit our Home Page

on the

World Wide Web!

http://www.aacr.org

Our web siteftatures ...

. AACR scientifio meeting schedule

. Table of Contents of AACR journals

. Instructions for Authors

. Information about AACR Research

Fellowships and Travel Awards

Plus . . .The latest AACR newsletter, and much more!

�! �

IkCER �

AMERICAN ASSOCIATION FOR CANCER RESEARCH

GUIDELINES FOR APPLICATION FOR ACTIVE AND

CORRESPONDING MEMBERSHIP

Notification of Candidate

MarchJuly

November

2� �

�

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific

society of over 1 1 ,500 laboratory and clinical cancer researchers, was

founded in 1907 to facilitate communication and dissemination of knowl-edge among scientists and others dedicated to the cancer problem; to

foster research in cancer and related biomedical sciences; to encourage the

presentation and discussion of new and important observations in the

field; to foster public education, science education, and training; and to

advance the understanding of cancer etiology, prevention. diagnosis, and

treatment throughout the world.Members of the AACR enjoy the following benefits:

I . the privilege of sponsoring a proffered paper (abstract) for consider-

ation for presentation at the AACR annual meeting;

2. an advance copy of the Program and Proceedings of the American

Associationfor Cancer Research that contains over 4,000 abstracts of

proffered papers presented at the annual meeting;

3. reduced registration rates at annual meetings;

4. priority notice of small, focussed meetings in the AACR’s exciting

series of Special Conferences in Cancer Research;

5. substantially reduced registration rates for Special Conferences;

6. opportunities for participation in AACR meetings in North America

and abroad with other scientific societies around the world;

7. receipt of AACR Newsletters and other important announcements;

8. early notification of and reduced rates for participation in the AACR

Employment Register:9. an up-to-date Membership Directory of over 1 1,500 member re-

searchers in the cancer field;

10. the professional benefits of the AACR’s public education activities

concerning funding for cancer research and press coverage of the

latest research findings:1 1 . the opportunity to participate in three Summer Workshops that foster

knowledge in the cancer field for young investigators;12. the facilitation of informal scientific exchange with leading research-

ers in the cancer field; and

13. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live inthe Americas. Individuals who have conducted two years of researchresulting in peer-reviewed publications relevant to cancer, or who have

made substantial contributions to cancer research in an administrative oreducational capacity, are eligible. If a candidate has conducted research in

an area of biomedical science related to cancer, he or she will qualify formembership. Evidence of patents relevant to cancer research may be

submitted as qualifications for membership in lieu of peer-reviewed

publications.

Corresponding membership is open to persons who are not residents

of the Americas. The qualifications for corresponding membership are thesame as those indicated above for active membership. Visiting scientists

from outside the Americas who intend to return to their countries of originby the anticipated time of election should apply for corresponding mem-bership. All other visiting scientists should apply for active membership

and transfer to corresponding status upon leaving the Americas.Graduate and medical students, postdoctoral fellows, and physicians in

training who do not yet meet the above qualifications for active orcorresponding membership should apply for associate membership.

Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application:January 1, May 1, and September 1 of each year. The Membership

Committee will review all complete applications for active membershipthat have been received by these deadlines and will submit recommenda-

tions on each candidate to the Board of Directors which formally elects allmembers. The same procedure is followed by the Special Memberships

Committee which receives applications for corresponding membership.

Candidates will be notified according to the following schedule:

Receipt of Application

in AACR Office _______________January 1

May I

September 1

A complete application consists of the following material:

1 . 6 copies of the form on the opposite side of this page, with all requestedinformation provided.

2. 5 copies of the candidate’s most current curriculum vitae and bibliog-

raphy.3. 5 copies of a letter of recommendation from a nominator who is an

active, corresponding, emeritus, or honorary member of the AACR (at

least one copy must be a signed, original letter). This letter shoulddescribe the candidate’s achievements in laboratory research, clinical

investigations, or epidemiological research, and it should affirm that

this research adheres to accepted ethical scientific standards. -OR- The

nominator may supply the responses requested at the bottom of the

application form in the section entitled “STATEMENT OF SUP-

PORT” (at least one copy of the form must be the signed original).

4. 5 copies of a letter of recommendation as described in Item 3 above

from a seconder who is an active, corresponding, emeritus, or honorary

member of the AACR (at least one copy must be a signed, originalletter). -OR- The seconder may supply the responses requested at thebottom of the application form in the section entitled “STATEMENT OF

SUPPORT “ (at least one copy of the form must be the signed original).

5. 5 reprints of each of two publications on which the candidate appears as

author. As noted above, evidence of patents developed by the candidate

may be submitted in lieu of one or both of the publications. If submittingpatents, supply patent number and year awarded.

All material should be collated into five complete sets with the originalapplication form as a covering document and sent to the address given

below. Questions regarding procedures for membership application mayalso be directed to the following address:

American Association for Cancer Research

Public Ledger Building, Suite 816

150 S. Independence Mall West

Philadelphia, PA 19 106-3483

Phone: 215/440-9300

FAX: 215/440-9313

E-mail: aacr@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of mem-

bership in the AACR. Active members must pay annual dues. In 1997

annual dues for active members are $175, $100 of which is designated forAACR journal subscriptions. Newly elected members of the AACR who

have already purchased subscriptions to Cancer Research, Clinical Can-

cer Research, Cell Growth & Differentiation, or Cancer Epidemiology,

Biomarkers & Prevention at the higher, nonmember rates will receivereimbursement of the unused portion of those subscriptions once their first

year’s membership dues are paid in full.

Corresponding members are required to pay dues ($90 in 1997) andmay, if they wish, subscribe to Cancer Research, Clinical Cancer Re-

search, Cell Growth & Differentiation, or Cancer Epidemiology, Biomar-

kers & Prevention at reduced member rates.

Applicants elected in March will be responsible for payment of that

year’s dues; applicants elected in July and November will pay dues for the

following year. Applicants elected in March and July will be eligible to

sponsor an abstract for the next annual meeting. Every effort will be made

to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.

Executive Director

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.Public Ledger Building ‘ Suite 816 150 5. Independence Mall West ‘ Philadelphia, PA 19106-3483

APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

NAME OF CANDIDATE:_________________________________________ DATE OF BIRTH:_________

LAST FIRST MI.

PRESENT POSITION/TITLE:

INSTITUTIONAL AFFILIATION:_________________________________________________________

INSTITUTIONAL ADDRESS:

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER:____________________________ FAX NUMBER:_________________________

E-MAIL NUMBER (CARRIER):

PRIMARY FIELD OF RESEARCH (Please check only one):

�Biochemistry and Biophysics �Biostatistics Carcinogenesis

_____Cellular Biology and Genetics _____Clinical Investigations Endocrinology

�Epidemiology Immunology Molecular Biology and Genetics

Preclinical Pharmacology and _____Virology _____Other:__________________________________

Experimental Therapeutics (Please specify)

ACADEMIC DEGREES (Including where and when granted)

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For

these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent

number and year awarded.)

CANDIDATE IS APPLYING FOR (Check one): E ACTIVE � CORRESPONDING MEMBERSHIP

CANDIDATE CANDIDATE

NOMINATED BY*:___________________________ SECONDED BY*:____________________________

(Please print) (Please print)

STATEMENT OF SUPPORTInstead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

I acknowledge by signing this statement of support that this candidate adheres to accepted ethical scientific standards and has or will make a

long-term contribution to cancer research.

Signature of Nominator* Date Signature of Seconder* Date

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.

(This form may be reproduced.) 1997

Margaret Foti, Ph.D.Executive Director

AMERICAN ASSOCIATION FOR CANCER RESEARCH

� GUIDELINES FOR APPLICATION FOR ASSOCIATE MEMBERSHIP]

QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students,

postdoctoral fellows, and physicians in training who are following a

course of study or who are working in a research program relevant to

cancer. Scientists in training who already have a substantial record of

publications may wish to apply for active or corresponding membership

which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific

society consisting of laboratory and clinical cancer researchers, was

founded in 1907 to facilitate communication and dissemination of knowl-

edge among scientists and others dedicated to the cancer problem; to

foster research in cancer and related biomedical sciences; to encourage

presentation and discussion of new and important observations in the

field; to foster public education, science education, and training; and to

advance the understanding of cancer etiology, prevention, diagnosis, and

treatment throughout the world. Associate members of the AACR enjoy

the following benefits:

I . the privilege of sponsoring a proffered paper (abstract) for consider-

ation for presentation at the AACR annual meeting provided that (a)the associate member is the presenter of the paper and (b) an active,

corresponding, emeritus, or honorary member in good standing of the

AACR also signs the abstract of the paper in support of the work. (In

this instance, the member who cosigns the abstract does not lose his

or her own sponsorship privilege.):2. an advance copy of the scientific Program and (if one has been

purchased by the associate member) the Proceedings ofthe American

Association for Cancer Research that contains over 4,000 abstracts ofproffered papers presented at the annual meeting:

3. the privilege of registering for the annual meeting at the low associate

member rate;4. preferred access to the AACR Employment Register;

5. optional subscriptions to the Association’s high-quality journals Can-

cer Research, Clinical Cancer Research, Cell Growth & Differenti-

ation, and Cancer Epidemiology, Biomarkers & Prevention at re-

duced member rates:

6. priority notification of events in the AACR’s series of special con-ferences on timely subjects in the field:

7. substantially reduced registration rates at special conferences;

8. the receipt of AACR newsletters, meeting announcements, and an

up-to-date Membership Directory:9. the opportunity to participate in three Summer Workshops that foster

knowledge in the cancer field for young investigators; and

10. the facilitation of informal scientific exchange with leading research-

ers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the

official application form on the reverse side of these instructions. Each

candidate for associate membership must be nominated by an active,

corresponding, emeritus, or honorary member in good standing of the

AACR. Three completed copies of the form should be submitted: at leastone of these copies must carry the original signatures of both the candidate

and the nominator. In addition, the candidate should submit one copy of

his or her curriculum vitae. The application form may be submitted to the

Association Office at any time.

After review of applications for associate membership, the ExecutiveDirector will notify candidates of their election or deferral within onemonth of the receipt of the application form. A check for one year’s duespayment must accompany the application. Dues for 1996 are $35 forassociate members residing in the Americas and $45 for residents of othercountries. For 1997 these rates are $45 and $55, respectively. This fee willbe refunded to any candidate deemed to be ineligible for associate mem-

bership. Checks should be in U.S. currency, made payable to AACR, Inc.,

and drawn on a U.S. bank. Send the three copies of the application form

and the appropriate dues payment to:

American Association for Cancer ResearchPublic Ledger Building, Suite 816

150 5. Independence Mall West

Philadelphia, PA 19106-3483Phone: 215/440-9300

FAX: 215/440-9313

E-mail: aacr@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be deter-mined by the AACR Board of Directors. Dues for 1996 have been set at$35 per year for residents of the Americas and $45 for residents of othercountries. For 1997 these rates are $45 and $55, respectively. If an

application is submitted by August 3 1 , the accompanying dues payment

will be credited to the current year. Candidates submitting applications

between September 1 and December 3 1 may indicate whether they wishtheir dues payments credited to the current or forthcoming year. Candi-

dates should be aware, however, that associate members may sponsor an

abstract for the annual meeting only if their dues for the current year are

paid. For example, an associate member submiuing an abstract in No-

vember 1996 for the forthcoming annual meeting must have paid dues for1996. Any newly elected associate members of the AACR who havealready purchased subscriptions to Cancer Research, Clinical Cancer

Research, Cell Growth & Differentiation, or Cancer Epidemiology, Bio-

markers & Prevention at the higher, nonmember rate will receive a refundfor the unused portion of that subscription upon receipt of their paymentfor a member’s subscription.

Each Fall the AACR will send to current associate members an invoicefor dues for the forthcoming year. Payment of this invoice must be

accompanied by a statement signed by the associate member’s current

registrar, dean, or department head, verifying the member’s current aca-

demic status. The Association’s By-Laws state that dues are payable for

each year in advance by January 1 of the year to which they should be

applied. An individual may be an associate member for a maximum offive years. Each year in which an individual pays dues will count as one

full year of associate membership. Thus, an associate member who pays

dues for I 996 may retain associate membership until December 3 1 , 2000.The Board of Directors may terminate the membership of an associatemember whose dues are in arrears for two years.

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Public Ledger Building ‘ Suite 816 . 150 5. Independence Mall West � Philadelphia, PA 19106-3483

APPLICATION FOR ASSOCIATE MEMBERSHIP I

NAME OF CANDIDATE:_______________________________________ DATE OF BIRTH:_________

LAST FIRST MI.

INSTITUTIONAL AFFILIATION:____________________________________________________________

INSTITUTIONAL ADDRESS:

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER:____________________________ FAX NUMBER:_________________________

PRESENT ACADEMIC STATUS/TITLE (Please check only one): E-MAIL NUMBER (CARRIER):

_____Graduate Student Medical Student

�Physician in Training Postdoctoral Fellow

PRIMARY FIELD OF RESEARCH (Please check only one):

Biochemistry and Biophysics Biostatistics Carcinogenesis

_____Cellular Biology and Genetics _____Clinical Investigations Endocrinology

�Epidemio1ogy Immunology _____Molecular Biology and Genetics

Preclinical Pharmacology and Virology Other:__________________________________

Experimental Therapeutics (Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide

information on degree currently being sought and the anticipated date of completion of this degree program.)

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the

candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

CANDIDATE NOMINATED BY*:___________________________________________________________

(Please print)

SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of

this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are

true.

Signature of Candidate:___________________________________________________________________ Date:___________________

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the

candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator*:_________________________________________________________________ Date:___________________

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. In addition, submit

one copy of your curriculum vitae. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year’s dues.

For 1996, dues are $35 for associate members residing in the Americas and $45 for residents of other countries. For 1997, these rates will be

$45 and $55, respectively.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:

The enclosed dues payment should be applied to the fl current Eli forthcoming calendar year.

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor

an abstract for presentation at the annual meeting in March on April of that year.) See Guidelines for Application on the reverse side of this

form for further instructions.

*Nominator must be active, corresponding, emeritus, or honorary member of the AACR.

(This form may be reproduced.) 1997

Guidelines for Submitting Disksto

American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

MacWrite WordPerfect (DOS, Windows,Microsoft Word (DOS, Windows, and Macintosh)

and Macintosh) XyWrite (DOS and Windows)

Also acceptable:

Ability Mass 1 1 SoloWriterAmiPro MS Windows Write SprintAM STEX MS Works StxAppleworks MS Works WP Mac SunWriteArborTEX Multimate SymphonyArborText Multimate Advantage TEXClarisWorks WP Nibia T�X78CPT 8000 Nisus (to ASCII file) Text EXecutiveCTOS Notewriter TexturesDiablo Obun Total WordDisplayWrite OfficeWriter TroffDuet PC Write iTEXEinstein PFS First Choice VolkswriterEnable Professional Write VuWriterEXP Q&A Write Wang OSFinal Word Quark XPress Wang WPSFullWrite RagTime MS Works Wang WriterGemWord Plus (to ASCII file) Window WorksIBM Writing Assistant Rich Text Format Windows WriteInterleaf RSG (to ASCII file) WiziWordLATEX Signature WordstarLatex SLITEX Wordstar 2000Leading Edge SmartWhere WriteNowLotus Manuscript SmartWrite II XeroxLotus Write

Software packages that we are unable to translate:

FrameMaker Ready, Set, GoPageMaker Scientific Writer

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple orWang computers can also be converted. Because of the file structures and internal coding, we cannot acceptdisks created on desktop publishing systems or those created on proprietary typesethng systems. We alsocannot guarantee that all special characters can be translated. Tabular and mathematical material, such asequations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the diskfile. The tables and equations will be keyed from this hard copy. We also need to know the name of the fileto be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system(e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK.DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.

DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. Whensubmitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along withthe required four hard copy printouts. Disks will ultimately be returned to the authors.

I See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the mostrecently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathe-matical and tabular material, however, will be processed in the traditional manner and may be excluded fromthe disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly releasedsoftware, or special characters.

Please label the outside of the disk with the journal name, the first author’s name, a partial title of themanuscript, and the name of the computer file used to access the manuscript on disk. To process your diskefficiently, we need the following information. Please be sure to provide ALL the information.

Name used to access paper on disk: _____________________

Name of computer used (e.g., IBM/PS2):Operating system and version (e.g., DOS 3.3):Word processing program and version (e.g., WordPerfect 5.0):.

[See reverse for acceptable programs.]

Manuscript number: _________________________________First author: ________________________________________

Corresponding author (if different from first author):

Telephone/FAX numbers: ____________________________

This form (both sides) may be reproduced.

Clinical and translational investigations continue to have a dramatic

impact on the treatment of cancer, making the need for up-to-date

information increasingly important. Every month, basic and clinical

cancer researchers turn to Clinical Cancer Research for the latest

reports of significant new studies. Act now to ensure you receive

research findings that are too important to miss.

SUBSCRIBE TODAY Call 1-800-875-2997 or 201-627-2427 or mall back the coupon below.

Please charge my

Account Name

Account No.

hxpiration Date

city State Zip

countr�

ugnature

L�IYes! I’d like to subscribe!Clinical Cancer ResearchVol. 3, 1997, 12 issues, ISSN 1078-0432

Institutional (Available only as a combined subscription with Cancer Research)

�:i $685� $1 30 should be added for delivery outside the U.S.

Individual� $1 05 non-member� $40 should be added for delivery outside the U.S.

MCR members: Contact the AACR for rates, (21 5) 440-9300.

Canada: Add 7% GST. MD: Add state sales tax.Individual subscriber: I certify that this subscription issolely for my personal use and will not be used in a library.

Signature

Name

Address

Method of Payment� Enclosed check or money order in U.S. dollars drawn

on U.S. bank. Payable to American Association forCancer Research.

� Institutional purchase order # is enclosed.

� MasterCard � VISA� American Express

�:i Please send me Instructions for Authors.

Mail coupon to: Clinical Cancer Research, P.O. Box 3000, Denville, NJ 07834-9359.

Those paying by credit card can fax to: (215) 440-9354.

AMERICAN ASSOCIATION FOR CANCER RESEARCH

1997 RESEARCH FELLOWSHIPS

For Young Scientists at the Postdoctoral or Clinical Fellow Level

. 1997 Research Fellowship in Clinical/Translational Research: This Fellowship,

sponsored by Amgen, Inc., will provide a one-year grant of $30,000 to a young

scientist in the U.S. or Canada engaged in meritorious clinical or translational

cancer research.

. 1997 Research Fellowship in Clinical Research: This Fellowship,

sponsored by Bristol-Myers Squibb Oncology, will provide a one-year grant

of $30,000 to a young scientist in the U.S. or Canada engaged in

meritorious clinical cancer research.

. 1997 Research Fellowship in Prevention Research: This Fellowship,sponsored by the Cancer Research Foundation of America, will provide a

one-year grant of $30,000 to a young scientist in the U.S. or Canada

engaged in meritorious cancer prevention research.

. 1997 Research Fellowships in Basic Research: Three Fellowships, sponsored by

The Sidney Kimmel Foundation for Cancer Research, Hoechst Marion Roussel, and

the AACR, will each provide a one-year grant of $30,000 to a young scientist in

the U.S. or Canada engaged in meritorious basic cancer research.

. The winners of the Research Fellowships will be announced at the AACR Annual

Meeting in San Diego, CA, in April 1997.

Eligibility

Candidates must have completed the M.D., Ph.D., or other doctoral degree. Candidates must

currently be a postdoctoral or clinical research fellow and must have been a fellow for at least

two years but not more than five years prior to the year of the award. Academic faculty holding

the rank of assistant professor or higher, graduate or medical students, government employees,

and employees of private industry are not eligible. A candidate need not be a member of the

AACR at the time of application, but he or she must be nominated by an AACR Member.

Associate Members may not be nominators.

Selection Process

Applications will receive careful scientific evaluation by a prestigious, multidisciplinary

Committee consisting of AACR Members who are experts in basic, clinical, and translational

cancer research. Applications must be submitted in complete form by February 14, 1997.

For Further Information/Application FormsAMERICAN ASSOCIATION FOR CANCER RESEARCH

Public Ledger Building, Suite 816150 South Independence Mall West

Philadelphia, PA 19106-3483Telephone: (215) 440-9300

FAX: (215) 440-9313e-mail: aacr@ aacr.org

AMERICAN ASSOCIATION FOR CANCER RESEARCH88th Annual Meeting

Frederick P. Li, Program Committee Chairperson

Clara Derber Bloomfield, Program Committee Co-Chairperson

Stephen H. Friend, Program Committee Co-Chairperson

San Diego Convention Center, San Diego, California

April 12-16, 1997

Titles of Major Session(Names of confirmed session organizers are in parentheses)

PLENARY SESSION

Genetic Predisposition to Cancer (Louise C. Strong)

SYMPOSIA

Genes, Cell Proliferation, and Antineoplastic Drugs (George

F. Vande Woude)

Diagnostic, Prognostic, and Therapeutic Aspects of Tumor

Suppressor Genes (David Sidransky)

Cell Cycle Regulation (Peggy J. Farnham)

Breast Cancer Genes (Barbara L. Weber)

Metastasis, Adhesion, and Angiogenesis: Mechanisms and

Therapeutic Strategies (Marilyn M. Cornwell and Elise

C. Kohn)

Novel Clinical Trials Based on Genetics and Molecular

Therapeutics (Stephen H. Friend)

Apoptosis and Cancer Chemotherapy (Michael B. Kastan)

Identification and Management of Genetic-High-Risk

Individuals (Albert de la Chapelle)

Demystifying the Role of Cytokines in Tumor

Immunobiology: Status and Future Utility (Michael A.

Caligiuri)

Telomerase and Clinical Applications (Titia de Lange)

Acute Myelocytic Leukemia (Clara Derber Bloomfield)

Prostate Cancer (Donald S. Coffey)

Colon Cancer (Margaret A. Tempero)

Signaling Pathways for Novel Therapeutics (Anthony J.

Pawson)

Animal Models for Functional Analysis of Tumor

Suppressor Genes (Terry A. Van Dyke)

New Techniques for Molecular Diagnostics (Eric S. Lander)

Mechanisms of Cellular Senescence (J. Carl Barrett)

Damage Response Pathways (Philip C. Hanawalt)

Gene Interactions with the Environment/Carcinogenesis

(Allan Balmain)

Epidemiology and Pathogenesis of Secondary Cancers

(Frederick P. Li)

CONTROVERSY SESSIONS

What Are the Appropriate Therapeutic Uses of

Hematopoietic Growth Factors? (Peter J. Quesenberry)

Estrogen Replacement Therapy: Beneficial or Harmful?

(Larry Norton)

What is the Value of Mammography in Young and

Genetically Susceptible Women?

Is the Time Right for Cancer Chemoprevention? (Edward

Bresnick)

Gene Patents: Help or Hindrance to Conquering Cancer?

What is the Role of Prophylactic Surgery in Breast and

Ovarian Cancer? (Samuel A. Wells, Jr.)

What Are the Appropriate Guidelines for the Use of

Archived Human Tissue?

How Robust Are AntisenselThird Strand Techniques for

Gene Disruption?

“MEET-THE-EXPERP’ SUNRISE SESSIONS

Angiogenesis

Gene Therapy (Jack A. Roth)

Strategies for Drug Development (Daniel D. Von Hoff)

Advances in Our Molecular Understanding of

Lymphoproliferative Disease (A. Thomas Look)

FHIT Gene (Kay Huebner)

Cancer Vaccines (David P. Carbone)

Lung Cancer

Costimulatory Molecules in Tumor Immunity

New Approaches to Overcoming Multidrug Resistance

(Alan F. List)

Advances in Oncologic Imaging (Michael J. Welch)

Retinoids and Cancer Prevention (Waun Ki Hong)

Mechanisms of Regulation of p53 Function (Guillermina

Lozano)

Cell Cycle Control of Genetic Stability (Geoffrey Wahi)

Farnesyl Transferase Inhibitors (Allen I. Oliff)

B ioinformatics/Genomics

DNA Methylation in Cancer (Stephen B. Baylin)

Chemoprevention in Transgenic Animals (James M. Phang)

Advances in Stem Cell Transplantation

Psychosocial Issues in Cancer

Advances in the Management of AIDS-related Malignancies

(Ellen G. Feigal)

Recent Developments in Our Understanding of Minimal

Residual Disease (John G. Gribben)

Ovarian Cancer Update (Robert C. Bast, Jr.)

The Biological Basis of the New International Classification

of Lymphoma (Elaine S. Jaffe)

Recent Developments in Radiotherapy

Colon Cancer Genes

Extracellular Connections

Barrett’s Esophageal Cancer and Tumor Progression Models

(Brian J. Reid)

H. Pylon

Transcriptional Models and Drug Discovery (William G.

Kaelin)

METHODS WORKSHOPS AND EDUCATIONAL SESSIONS

To be announced

Abstract Deadline: November 12, 1996

Further Information: AACR Office . � Ledger Building . Suite

816 . 150 S. Independence Mall West . Philadelphia, PA 19106-

3483 . TELEPHONE: (215) 440-9300 . FAX: (215) 440-9313.

Email: aacr@aacr.org . For up-to-date information visit the AACR

Website at http:llwww.aacr.org

AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Basic and Clinical Aspects ofBreast Cancer

March 7-12, 1997The Keystone Resort, Keystone , Colorado

CONFERENCE CHAIRPERSONS

J. Carl Barrett I Research Triangle Park, NCKaren S.H. Antman I New York, NY

Mary-Claire King I Seattle, WA

SCIENTIFIC PROGRAM

Keynote AddressesMary-Claire King I Seattle, WAKaren S.H. Antman I New York, NY

Basic Biology of the BreastJos#{233}Russo I Philadelphia, PA

Marc E. Uppman I Washington, D.C.C. Kent Osborne I San Antonio, TX

Molecular and Cellular Aspects of BreastCancerJerry W. Shay I Dallas, TXMina J. Bissell I Berkeley, CAMartha R. Stampfer I Berkeley, CA

Genetic Predisposition to Breast CancerDavid E. Goldgar I Lyon, FranceP. Andrew Futreal I Durham, NC

Mechanisms of Hormone ActionV. Craig Jordan I Chicago, ILMyles A. Brown I Boston, MAKenneth S. Korach I Research Triangle Park, NC

BRCA1 and BRCA2 Function/BiochemistryRoy A. Jensen I Nashville, TNWen-Hwa Lee I San Antonio, TXDavid M. Uvingston I Boston, MAFrank J. Calzone I Thousand Oaks, CA

Experimental Models of Breast CancerTak W. Mak I Toronto, Ontano, Canada

Michael N. Gould I Madison, WI

Epidemiology of Breast CancerWalter C. Willett I Boston, MAMaureen Henderson I Seattle, WAMalcolm C. Pike I Los Angeles, CA

Mary S. Wolff I New York, NY

Clinical Aspects of Breast CancerJudy E. Garber I Boston, MAJeffrey T. Holt I Nashville, TNM. John Kennedy I Baltimore, MD

Applicants are encouraged to submit abstractsfor poster presentation.

Application deadline: January 3, 1997

Information and Application Forms

American Association for Cancer ResearchPublic Ledger Building, Suite 816150 South Independence Mall WestPhiladelphia, PA 19106-348321 5-440-9300 21 5-440-931 3 (FAX)aacr@ aacr.org (E-mail)http:llwww.aacr.org